Anti-mesothelin antibodies and uses thereof

Monoclonal anti-mesothelin antibodies and CARs provide targeted therapy for mesothelin-expressing cells, addressing poor prognosis in cancers and inflammatory diseases by inducing cell lysis and recruiting drugs, enhancing treatment efficacy across various disease types.

CN119095879APending Publication Date: 2024-12-06PHANES THERAPEUTICS LTD
View PDF 28 Cites 0 Cited by

Patent Information

Application Number
CN202380028405.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-12-01
Filing Date
2023-03-01
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Current treatments for cancers and inflammatory diseases lack effective targeting mechanisms for mesothelin-expressing cells, which are associated with poor prognosis and tumor invasion.

Method used

Development of monoclonal anti-mesothelin antibodies and chimeric antigen receptors (CARs) that specifically bind to mesothelin, inducing effector-mediated tumor cell lysis and recruiting conjugated drugs, and can be administered in pharmaceutical compositions to target and treat various cancers and inflammatory diseases.

Benefits of technology

The antibodies and CARs effectively target and kill mesothelin-expressing cells, providing therapeutic options for a range of cancers and inflammatory diseases, including solid and liquid tumors, with potential for improved treatment efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005047820560000201
    Figure BDA0005047820560000201
  • Figure BDA0005047820560000211
    Figure BDA0005047820560000211
  • Figure BDA0005047820560000471
    Figure BDA0005047820560000471
Patent Text Reader

Abstract

Anti-mesothelin antibodies and antigen-binding fragments thereof and chimeric antigen receptors (CARs) comprising an anti-mesothelin antigen-binding domain are described. Also described are nucleic acids encoding the antibodies and CARs, compositions comprising the antibodies and CARs, methods of making the antibodies and CARs, and methods of using the antibodies and CARs to treat or prevent diseases such as cancer and / or inflammatory diseases and / or autoimmune diseases.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to U.S. Provisional Application No. 63 / 269,355 filed on March 15, 2023 and U.S. Provisional Application No. 63 / 385,660 filed on December 1, 2022. The disclosure of each is incorporated herein by reference in its entirety. Field of the Invention

[0003] The present invention relates to monoclonal anti-mesothelin antibodies and chimeric antigen receptors (CARs) comprising anti-mesothelin antigen binding domains, nucleic acids and expression vectors encoding the antibodies and CARs, recombinant cells comprising the vectors, and compositions, the compositions comprising the above antibodies, CARs, and host cells comprising the CARs. The present invention also provides methods for preparing the antibodies and CARs, and methods for using the antibodies and CARs to treat diseases, the diseases including cancer, inflammatory diseases, autoimmune diseases, and / or related complications.

[0004] References to electronically submitted sequence listings

[0005] This application contains a sequence listing submitted electronically. The electronic sequence listing (065799.37WO1 sequence listing.xml, size: 69,020 bytes, created on February 22, 2023) is hereby incorporated by reference in its entirety. Background of the Invention

[0007] Mesothelin (MSLN) is a 40KDa glycosylphosphatidylinositol (GPI) anchored glycoprotein whose normal expression is strictly restricted to the surface of mesothelial cells. The physiological function of MSLN remains elusive, because mice with knockout of the mesothelin gene do not show a significant phenotype, suggesting that the protein is dispensable for any important function (Bera, TK et al., Mol. Cell. Biol, 2000, 20: 2902-2906). On the other hand, mesothelin is overexpressed in many cancer cells, including mesothelioma, pancreatic cancer, ovarian cancer and lung adenocarcinoma ( NG, Am J Surg Pathol, 2003, 27: 1418-28). Overexpression of mesothelin is associated with poor prognosis of the disease. Mechanistically, the interaction between MSLN and CA125 / MUC16 is associated with tumor invasion and metastasis (Rump, A. et al., J Biol Chem. 2004, 279: 9190-9198; Chen, SH et al., Science Reports. 2013, 3: 1870). Therefore, selecting a suitable MSLN monoclonal antibody can target tumor cells for immune cell killing and reduce tumor invasiveness. SUMMARY OF THE INVENTION

[0009] In one general aspect, the invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds mesothelin.

[0010] An isolated monoclonal antibody or antigen-binding fragment thereof is provided, which comprises a heavy chain variable region comprising a heavy chain complementary determining region 1 (HCDR1), HCDR2, and HCDR3, and a light chain variable region comprising a light chain complementary determining region 1 (LCDR1), LCDR2, and LCDR3, each having the following polypeptide sequence:

[0011] (1) SEQ ID NO: 3, 4, 5, 6, 7 and 8, or SEQ ID NO: 9, 10, 11, 12, 13 and 14;

[0012] (2) SEQ ID NOs: 17, 18, 19, 20, 21 and 22, or SEQ ID NOs: 23, 24, 25, 26, 27 and 28;

[0013] (3) SEQ ID NOs: 31, 32, 33, 34, 35 and 36, or SEQ ID NOs: 37, 38, 39, 40, 41 and 42;

[0014] (4) SEQ ID NOs: 60, 61, 62, 63, 64 and 65, or SEQ ID NOs: 66, 67, 68, 69, 70 and 71;

[0015] Wherein, the antibody or antigen-binding fragment thereof specifically binds to mesothelin, preferably human mesothelin.

[0016] In certain embodiments, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region whose polypeptide sequence is at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 1, 15, 29 or 58, or comprises a light chain variable region whose polypeptide sequence is at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 2, 16, 30 or 59.

[0017] In certain embodiments, the isolated monoclonal antibody or antigen-binding fragment thereof comprises:

[0018] (a) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 1 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 2;

[0019] (b) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 15 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 16;

[0020] (c) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 29 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 30; or

[0021] (d) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 58 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 59.

[0022] In certain embodiments, the isolated monoclonal antibody or antigen-binding fragment thereof binds to mesothelin and is capable of inducing effector-mediated tumor cell lysis through antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) and / or complement-dependent cytotoxicity (CDC); and / or mediates the recruitment of conjugated drugs; and / or forms a bispecific antibody with another monoclonal antibody or antigen-binding fragment thereof having a cancer-killing effect.

[0023] In certain embodiments, the isolated monoclonal antibody or antigen-binding fragment thereof is chimeric.

[0024] In certain embodiments, the isolated monoclonal antibody or antigen-binding fragment thereof is human or humanized. In certain embodiments, the humanized monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence that is at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to any one of SEQ ID Nos: 43-46, 52-55, 72-75; or a light chain variable region having a polypeptide sequence that is at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to any one of SEQ ID Nos: 47-51, 56-57, 76-78.

[0025] In certain embodiments, the humanized monoclonal antibody or antigen-binding fragment thereof comprises:

[0026] (1) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 43 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 47;

[0027] (2) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 43 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 48;

[0028] (3) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 43 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 49;

[0029] (4) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 43 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 50;

[0030] (5) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 43 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 51;

[0031] (6) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 44 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 47;

[0032] (7) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 44 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 48;

[0033] (8) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 44 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 49;

[0034] (9) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 44 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 50;

[0035] (10) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 44 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 51;

[0036] (11) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 45 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 47;

[0037] (12) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 45 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 48;

[0038] (13) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 45 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 49;

[0039] (14) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 45 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 50;

[0040] (15) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 45 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 51;

[0041] (16) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 46 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 47;

[0042] (17) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 46 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 48;

[0043] (18) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 46 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 49;

[0044] (19) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 46 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 50;

[0045] (20) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 46 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 51;

[0046] (21) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 52 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 56;

[0047] (22) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 52 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 57;

[0048] (23) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 53 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 56;

[0049] (24) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 53 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 57;

[0050] (25) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 54 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 56;

[0051] (26) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 54 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 57;

[0052] (27) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 55 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 56;

[0053] (28) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 55 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 57;

[0054] (29) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 72 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 76;

[0055] (30) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 72 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 77;

[0056] (31) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 72 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 78;

[0057] (32) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 73 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 76;

[0058] (33) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 73 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 77;

[0059] (34) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 73 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 78;

[0060] (35) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 74 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 76;

[0061] (36) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 74 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 77;

[0062] (37) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 74 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 78;

[0063] (38) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 75 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 76;

[0064] (39) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 75 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 77; or

[0065] (40) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 75 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 78.

[0066] Also provided is an isolated nucleic acid encoding the monoclonal antibody or antigen-binding fragment thereof or the bispecific antibody of the invention.

[0067] Also provided are vectors comprising an isolated nucleic acid encoding the monoclonal antibody or antigen-binding fragment thereof or the bispecific antibody or antigen-binding fragment thereof of the invention.

[0068] The present invention also provides a host cell comprising a vector, wherein the vector comprises an isolated nucleic acid encoding the monoclonal antibody or antigen-binding fragment thereof or the bispecific antibody or antigen-binding fragment thereof of the present invention.

[0069] In certain embodiments, a pharmaceutical composition is provided, comprising an isolated monoclonal antibody or antigen-binding fragment thereof or an isolated bispecific antibody or antigen-binding fragment thereof of the present invention and a pharmaceutically acceptable carrier.

[0070] The present invention also provides a method for specifically targeting mesothelin on the surface of cancer cells in a subject in need thereof, the method comprising administering the pharmaceutical composition of the present invention to the subject.

[0071] The present invention also provides a method for treating cancer in a subject in need, including applying the pharmaceutical composition of the present invention to the subject.Cancer can be any liquid or solid cancer, for example, it can be selected from but not limited to lung cancer, gastric cancer, esophageal cancer, bile duct cancer, cholangiocarcinoma, colon cancer, hepatocellular carcinoma, renal cell carcinoma, bladder urothelial carcinoma, metastatic melanoma, breast cancer, ovarian cancer, cervical cancer, head and neck cancer, pancreatic cancer, glioma, glioblastoma, mesothelioma and other solid tumors; and non-Hodgkin's lymphoma (NHL), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), multiple myeloma (MM), acute myeloid leukemia (AML) and other liquid tumors.

[0072] The present invention also provides a method of treating an inflammatory and / or autoimmune disease in a subject in need thereof, the method comprising administering a pharmaceutical composition of the present invention to the subject.

[0073] The present invention also provides a method for preparing the monoclonal antibody or antigen-binding fragment thereof or the bispecific antibody or antigen-binding fragment thereof of the present invention, which comprises culturing cells containing a nucleic acid encoding the monoclonal antibody or antigen-binding fragment thereof or the bispecific antibody or antigen-binding fragment thereof under conditions for preparing the monoclonal antibody or antigen-binding fragment thereof or the bispecific antibody or antigen-binding fragment thereof, and recovering the monoclonal antibody or antigen-binding fragment thereof or the bispecific antibody or antigen-binding fragment thereof from the cells or culture.

[0074] The present invention also provides a method for preparing a pharmaceutical composition comprising the monoclonal antibody or its antigen-binding fragment or the bispecific antibody or its antigen-binding fragment of the present invention, comprising combining the monoclonal antibody or its antigen-binding fragment or the bispecific antibody or its antigen-binding fragment with a pharmaceutically acceptable carrier to obtain the pharmaceutical composition.

[0075] The present invention also provides a method for detecting the level of mesothelin in a subject. The method comprises (a) obtaining a sample from a subject; (b) contacting the sample with an antibody or antigen-binding fragment of the present invention; (c) determining the level of mesothelin in the subject. In certain embodiments, the sample is a tissue sample. For example, the tissue sample can be a cancer tissue sample. In certain embodiments, the sample is a blood sample.

[0076] In another general aspect, the present invention relates to a chimeric antigen receptor (CAR) construct that induces T cell-mediated cancer killing, wherein the CAR construct comprises at least an antigen binding domain that specifically binds to human mesothelin, a hinge region, a transmembrane region, and an intracellular signaling domain.

[0077] The present invention provides an isolated polynucleotide comprising a nucleic acid sequence encoding a chimeric antigen receptor (CAR). The CAR may include: (a) an extracellular domain comprising at least one antigen binding domain that specifically binds to mesothelin; (b) a hinge region; (c) a transmembrane region; (d) an intracellular signal transduction domain.

[0078] In certain embodiments, the antigen binding domain comprises a heavy chain variable region comprising heavy chain complementary determining region 1 (HCDR1), HCDR2, HCDR3, and a light chain variable region comprising light chain complementary determining region 1 (LCDR1), LCDR2, and LCDR3, each having the following polypeptide sequence:

[0079] (1) SEQ ID NO: 3, 4, 5, 6, 7 and 8, or SEQ ID NO: 9, 10, 11, 12, 13 and 14;

[0080] (2) SEQ ID NOs: 17, 18, 19, 20, 21 and 22, or SEQ ID NOs: 23, 24, 25, 26, 27 and 28;

[0081] (3) SEQ ID NOs: 31, 32, 33, 34, 35 and 36, or SEQ ID NOs: 37, 38, 39, 40, 41 and 42;

[0082] (4) SEQ ID NOs: 60, 61, 62, 63, 64 and 65, or SEQ ID NOs: 66, 67, 68, 69, 70 and 71;

[0083] Wherein, the antigen binding domain specifically binds to mesothelin, preferably human mesothelin.

[0084] In certain embodiments, the antigen binding domain comprises a heavy chain variable region having a polypeptide sequence that is at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO:1, 15, 29 or 58; or comprises a light chain variable region having a polypeptide sequence that is at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO:2, 16, 30 or 59.

[0085] In certain embodiments, the antigen binding domain comprises:

[0086] (a) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 1 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 2;

[0087] (b) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 15 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 16;

[0088] (c) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 29 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 30; or

[0089] (d) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 58 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 59.

[0090] In certain embodiments, the antigen binding domain is humanized and includes a heavy chain variable region having a polypeptide sequence that is at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID Nos: 43-46, 52-55, or 72-75, or a light chain variable region having a polypeptide sequence that is at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to any one of SEQ ID Nos: 47-51, 56-57, or 76-78.

[0091] In certain embodiments, the antigen binding domain is humanized and comprises:

[0092] (1) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 43 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 47;

[0093] (2) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 43 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 48;

[0094] (3) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 43 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 49;

[0095] (4) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 43 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 50;

[0096] (5) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 43 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 51;

[0097] (6) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 44 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 47;

[0098] (7) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 44 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 48;

[0099] (8) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 44 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 49;

[0100] (9) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 44 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 50;

[0101] (10) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 44 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 51;

[0102] (11) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 45 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 47;

[0103] (12) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 45 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 48;

[0104] (13) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 45 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 49;

[0105] (14) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 45 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 50;

[0106] (15) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 45 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 51;

[0107] (16) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 46 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 47;

[0108] (17) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 46 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 48;

[0109] (18) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 46 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 49;

[0110] (19) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 46 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 50;

[0111] (20) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 46 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 51;

[0112] (21) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 52 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 56;

[0113] (22) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 52 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 57;

[0114] (23) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 53 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 56;

[0115] (24) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 53 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 57;

[0116] (25) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 54 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 56;

[0117] (26) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 54 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 57;

[0118] (27) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 55 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 56;

[0119] (28) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 55 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 57;

[0120] (29) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 72 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 76;

[0121] (30) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 72 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 77;

[0122] (31) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 72 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 78;

[0123] (32) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 73 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 76;

[0124] (33) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 73 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 77;

[0125] (34) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 73 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 78;

[0126] (35) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 74 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 76;

[0127] (36) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 74 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 77;

[0128] (37) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 74 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 78;

[0129] (38) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 75 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 76;

[0130] (39) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 75 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 77; or

[0131] (40) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 75 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 78.

[0132] In certain embodiments, the antigen binding domain is a single chain variable fragment (scFv).

[0133] In certain embodiments, the antigen binding domain is a humanized single chain variable fragment (scFv).

[0134] In certain embodiments, the chimeric antigen receptor (CAR) comprises one or more antigen binding domains.

[0135] In certain embodiments, the intracellular signaling domain comprises one or more co-stimulatory domains and one or more activation domains.

[0136] The present invention also provides chimeric antigen receptors (CARs) encoded by the isolated polynucleotides of the present invention.

[0137] The present invention also provides a vector comprising an isolated polynucleotide comprising a nucleic acid encoding CARs.

[0138] The present invention also provides a host cell comprising the vector.

[0139] In some embodiments, the host cell is a T cell, preferably a human T cell. In some embodiments, the host cell is a NK cell, preferably a human NK cell. For example, a T cell or a NK cell can be transformed into a cell expressing the CAR of the present invention to treat a disease such as cancer.

[0140] The present invention also provides a method for preparing a host cell expressing a chimeric antigen receptor (CAR) of the present invention. The method includes transducing T cells or NK cells with a vector containing an isolated nucleic acid encoding the CARs of the present invention.

[0141] The present invention also provides a method for preparing the CAR-T cell or CAR-NK cell of the present invention. The method includes culturing a T cell or NK cell containing an isolated polynucleotide containing a nucleic acid encoding a chimeric antigen receptor (CAR) of the present invention under conditions for preparing a CAR-T cell or a CAR-NK cell, and recovering the CAR-T cell or the CAR-NK cell.

[0142] The present invention also provides a method for preparing an RNA engineered cell population comprising a chimeric antigen receptor (CAR) of the present invention. The method includes contacting a cell with an isolated polynucleotide containing a nucleic acid encoding a chimeric antigen receptor (CAR), wherein the isolated polynucleotide is an in vitro transcribed RNA or a synthetic RNA.

[0143] The present invention also provides a method for treating cancer in a subject in need, comprising administering the CAR-T cells and / or CAR-NK cells of the present invention to the subject. The cancer can be any liquid or solid cancer, for example, it can be selected from but not limited to lung cancer, gastric cancer, colon cancer, hepatocellular carcinoma, renal cell carcinoma, bladder urothelial carcinoma, metastatic melanoma, breast cancer, ovarian cancer, cervical cancer, head and neck cancer, pancreatic cancer, glioma, glioblastoma, mesothelioma and other solid tumors, as well as non-Hodgkin's lymphoma (NHL), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), multiple myeloma (MM), acute myeloid leukemia (AML) and other liquid tumors.

[0144] In certain embodiments, the method of treating cancer in a subject in need thereof further comprises administering to the subject in need thereof a drug that increases the efficiency of cells expressing the CAR molecule.

[0145] In certain embodiments, the method of treating cancer in a subject in need thereof further comprises administering to the subject in need thereof a drug that improves one or more side effects associated with administering cells expressing a CAR molecule.

[0146] In certain embodiments, the method of treating cancer in a subject in need thereof further comprises administering to the subject in need thereof a medicament for treating a disease associated with mesothelin.

[0147] BRIEF DESCRIPTION OF THE DRAWINGS

[0148] The foregoing summary of the invention and the following detailed description of the preferred embodiments of the present application will be better understood when read in conjunction with the accompanying drawings. It should be understood, however, that the present application is not limited to the specific embodiments shown in the accompanying drawings.

[0149] Figures 1A-1D Binding of purified chimeric anti-mesothelin mAbs (VH and VL regions of mouse mAbs fused to constant regions of human IgG1 heavy chain and kappa light chain, respectively) to immobilized recombinant mesothelin in an ELISA assay (method as described in Example 3). Antigen was human mesothelin (296-580) tagged with 6xHis at the C-terminus (Biosciences, Inc., Newark, DE; Catalog #: MSN-H5223). Isotype control (IgG1), negative control antibody; secondary antibody only, secondary antibody alone was added as negative control.

[0150] Figure 2A-2C The results show that the anti-mesothelin monoclonal antibody is comparable to NCI-N87 ( Figure 2A-2B ) or NCI-H226 cell line ( Figure 2C The negative control antibody was the isotype control antibody IgG1.

[0151] Figures 3A-3E Purified human anti-mesothelin monoclonal antibody binds to immobilized recombinant mesothelin in an ELISA assay (see Example 3 for methods). Antigen is human mesothelin (296-580) tagged with 6xHis at the C-terminus (Biosciences Inc., Catalog #: MSN-H5223). 10F5-C, chimeric version of 10F5; 4F8 and 2G11 use the same naming convention. Isotype control (IgG1), negative control antibody; Secondary antibody only, only secondary antibody was added as a negative control.

[0152] Figures 4A-4E The purified human anti-mesothelin mAb was compared with NCI-N87 ( Figures 4A-4D ) or NCI-H226 cell line ( Figure 4E ) binding. Isotype control (IgG1), negative control antibody; Secondary antibody only, only secondary antibody was added as negative control. 10F5-C, chimeric version of 10F5; 4F8 and 2G11 use the same naming convention. DETAILED DESCRIPTION OF THE INVENTION

[0154] Various publications, articles, and patents are cited or described in the background and throughout the specification; each of these references is incorporated herein by reference in its entirety. The discussion of documents, acts, materials, devices, articles, etc. in this specification is intended to provide background information for the present invention. Such discussion does not imply that any or all of the above matters constitute part of the prior art for any disclosed or claimed invention.

[0155] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by ordinary technicians in the field to which the invention belongs. Otherwise, certain terms used herein have the meanings specified in the specification.

[0156] It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.

[0157] Unless otherwise indicated, any numerical value (e.g., a concentration or concentration range described herein) is understood to be modified by the term "about" in any case. Therefore, numerical values ​​generally include ±10% of the numerical value. For example, a concentration of 1 mg / mL includes 0.9 mg / mL to 1.1 mg / mL. Similarly, a concentration range of 1% to 10% (w / v) includes 0.9% (w / v) to 11% (w / v). As used herein, unless the context clearly provides otherwise, the use of numerical ranges clearly includes all possible subranges, all individual numerical values ​​within the range, including integers within the range and fractions of the numerical values.

[0158] Unless otherwise specified, the word "at least" before a series of elements should be understood to refer to every element in the series. Those skilled in the art can identify or determine many equivalent solutions that are equivalent to the specific embodiments described in the present invention by means of no more than routine experiments. These equivalent solutions are all included in the present invention.

[0159] As used herein, it is understood that the terms "comprises," "including," "covers," "has," "has," "includes," or "comprising" or any other variation are meant to include the stated integer or group of integers but not to exclude any other integer or group of integers, and are non-exclusive or open-ended. For example, a composition, mixture, process, method, article, or apparatus that includes a group of elements is not necessarily limited to only those elements but may include other elements not expressly listed or inherent to the composition, mixture, process, method, article, or apparatus. In addition, unless expressly stated otherwise, "or" is inclusive and not exclusive. For example, any of the following conditions satisfies A or B: A is true (or present) and B is false (or absent), A is false (or absent) and B is true (or present), and both A and B are true (or present).

[0160] As used herein, the conjunction term "and / or" between multiple listed elements is understood to include separate and combined options. For example, when two elements are connected by "and / or", the first case is that the first element is applicable, while the second element is not applicable. The second case is that the second element is applicable, while the first element is not applicable. The third case is that both the first and second elements are applicable. It should be understood that any of these cases are within the meaning of the term "and / or" used herein, and therefore meet the requirements of the term. Multiple cases that are applicable at the same time are also considered to be within the meaning, and therefore also meet the requirements of the term "and / or".

[0161] As used herein, as used throughout the specification and claims, the term "consisting of, or variations such as "consisting of," or "composed of," means that any stated integer or group of integers is included, but any additional integer or group of integers cannot be added to a specified method, structure, or composition.

[0162] As used herein, as used throughout the specification and claims, the term "consisting essentially of, or variations such as "consisting essentially of, or "consisting essentially of, means including any stated integer or group of integers, and optionally including any stated integer or group of integers that does not materially change the basic or novel characteristic of a specified method, structure, or composition. See MPEP §2111.03.

[0163] As used herein, "subject" means any animal, preferably a mammal, most preferably a human. The term "mammal" as used herein includes any mammal. Examples of mammals include, but are not limited to, cows, horses, sheep, pigs, cats, dogs, mice, rats, rabbits, guinea pigs, monkeys, humans, etc., more preferably humans.

[0164] “Right,” “left,” “lower,” and “upper” designate directions in the drawings to which reference may be made.

[0165] It should also be understood that when referring to dimensions or features of components of the preferred invention, the terms "approximately", "about", "generally", "substantially" and similar terms used herein indicate that the described dimensions / features are not strict boundaries or parameters and do not exclude minor variations thereof that are functionally the same or similar, as understood by those of ordinary skill in the art. At a minimum, such references including numerical parameters also include some variations that are calculated using mathematical and industrial principles recognized in the art (e.g., rounding, measurement or other systematic errors, manufacturing tolerances, etc.) and do not change the least significant digit.

[0166] The term "identical" or percent "identity" in the context of two or more nucleic acid or polypeptide sequences (e.g., anti-mesothelin antibodies and polynucleotides encoding the same, chimeric antigen receptors (CARs) comprising a mesothelin-specific antigen binding domain and polynucleotides encoding the same) means that two or more sequences or subsequences are identical or that a specified percentage of amino acid residues or nucleotides are identical in the sequences, when compared and aligned for maximum correspondence using one of the following sequence comparison algorithms or by visual inspection.

[0167] For sequence comparison, usually one sequence is used as a reference sequence to which a test sequence is compared. When a sequence comparison algorithm is used, the test sequence and the reference sequence are input into a computer, subsequence coordinates are specified if necessary, and sequence algorithm program parameters are specified. Subsequently, the sequence comparison algorithm calculates the percent sequence identity between the test sequence and the reference sequence based on the specified program parameters.

[0168] Sequences can be optimally aligned for comparison, for example, using the local homology algorithm of Smith and Waterman (Adv. Appl. Math. 1981; 2: 482), the homology alignment algorithm of Needleman and Wensch (J. Mol. Biol. 1970; 48: 443), the similarity search method of Pearson and Lipman (Proc. Nat'l. Acad. Sci. USA 1988; 85: 2444), or using computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Avenue, Madison, Wisconsin), or by visual inspection (see "A Laboratory Manual of Molecular Biology", FM Ausubel et al., eds., Laboratory Manual, a joint venture between Green Publishing Co., Ltd. and John Wiley & Sons, Inc., Supplement (Ausubel) 1995).

[0169] Examples of algorithms suitable for determining sequence identity and sequence similarity are BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., J. Mol. Biol. 1990; 215: 403-410 and Altschul et al., Nucleic Acids Res. Vol. 25; 3389-3402, respectively. Software for performing BLAST analysis is publicly available through the National Center for Biotechnology Information. The algorithm first identifies short sequences of length W in the query sequence, finds high-scoring sequence pairs (HSPs), and matches or satisfies a positive threshold T when these sequences are aligned with sequences of the same length in the database sequence. T is referred to as the neighborhood sequence score threshold (Altschul et al., supra). These initial neighborhood sequence matches serve as seeds for starting searches to find longer HSPs containing them. Then, these short sequences are extended to both sides along each sequence until the cumulative alignment score reaches a maximum.

[0170] The cumulative score for nucleotide sequences is calculated using the following parameters: parameters M (reward score for matching residue pairs; always greater than 0) and N (penalty score for mismatched residue pairs; always less than 0). For amino acid sequences, the cumulative score is calculated using a scoring matrix. Extension of sequence hits in each direction stops in the following cases: when the cumulative alignment score drops by X from its maximum achieved value; when the cumulative score becomes zero or lower due to the accumulation of one or more negative-scoring residue pairs; or when the end of any sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment program. The BLASTN program (for nucleotide sequences) uses default values ​​in which the sequence length (W) is 11, the expectation value (E) is 10, M=5, N=-4, and two chains are compared. For amino acid sequences, the BLASTP program uses default values ​​in which the sequence length (W) is 3, the expectation value (E) is 10, and the BLOSUM62 scoring matrix is ​​used (see Henikoff and Henikoff, Proc. Natl. Acad. Sci. USA, 1989; 89: 10915).

[0171] In addition to calculating the percentage of sequence similarity, the BLAST algorithm also performs a statistical analysis of the similarity between two sequences (e.g., Karlin and Altschul, Proc. Nat'l. Acad. Sci. USA, 1993; 90: 5873-5787). One of the similarity measures provided by the BLAST algorithm is the minimum total probability (P(N)), which indicates the probability that two nucleotide or amino acid sequences will match by chance. For example, if the minimum total probability in the comparison of the test nucleic acid with the reference nucleic acid is less than about 0.1, the nucleic acid is considered to be similar to the reference sequence, more preferably less than about 0.01, and most preferably less than about 0.001.

[0172] A further indication that two nucleic acid sequences or polypeptide sequences are substantially identical is that the polypeptide encoded by one of the nucleic acid sequences is immunologically cross-reactive with the polypeptide encoded by the other nucleic acid sequence, as described below. Thus, if two polypeptides differ only in conservative amino acid substitutions, then the two polypeptides may be substantially identical. If under specified conditions, the two molecules can hybridize with each other, then the two nucleic acid sequences are also substantially identical.

[0173] As used herein, the term "isolated" refers to a biological component (such as a nucleic acid, polypeptide or protein) that has been substantially separated, produced separately or purified from other biological components of the organism in which it naturally occurs (i.e., other chromosomal and non-chromosomal DNA and RNA and proteins). Thus, "isolated" nucleic acids, polypeptides and proteins include nucleic acids and proteins purified by standard purification methods. "Isolated" nucleic acids, polypeptides and proteins can also be part of a mixture and separated, and the composition is not part of the natural environment of the nucleic acid, peptide or protein. The term also includes nucleic acids, polypeptides and proteins prepared by recombinant expression in a host cell and nucleic acids prepared by chemical synthesis.

[0174] As used herein, the term "polynucleotide" (also referred to as "nucleic acid molecule", "nucleotide" or "nucleic acid") refers to any polyribonucleotide or polydeoxyribonucleotide, which may be unmodified RNA or DNA, or modified RNA or DNA. "Polynucleotide" includes, but is not limited to, single-stranded and double-stranded DNA, DNA composed of a mixture of single-stranded and double-stranded regions, single-stranded and double-stranded RNA, RNA composed of a mixture of single-stranded and double-stranded regions, hybrid molecules comprising DNA and RNA, which may be single-stranded, but more typically are double-stranded or composed of a mixture of single-stranded and double-stranded regions. In addition, "polynucleotide" refers to a triple-stranded region of RNA or DNA or RNA and DNA. The term polynucleotide also includes DNA or RNA containing one or more modified bases, as well as DNA or RNA with a modified backbone for stability or other reasons. "Modified" bases include, for example, trimethylated bases and rare bases, such as inosine. A variety of modifications can be made to DNA and RNA; thus, "polynucleotides" include chemically, enzymatically, or metabolically modified forms of polynucleotides commonly found in nature, as well as chemical forms of DNA and RNA unique to viruses and cells."Polynucleotides" also include relatively short nucleic acid chains, often referred to as oligonucleotides.

[0175] As used herein, the term "vector" is a replicon into which another nucleic acid segment can be operably inserted to achieve replication or expression of that segment.

[0176] As used herein, the term "host cell" refers to a cell comprising a nucleic acid molecule of the present invention. A "host cell" can be any type of cell, such as a primary cell, a cultured cell, or a cell from a cell line. In one embodiment, a "host cell" is a cell transfected with a nucleic acid molecule of the present invention. In another embodiment, a "host cell" is a progeny or potential progeny of such a transfected cell. The progeny of a cell may or may not be identical to the parent cell, for example, due to mutations or environmental influences that may occur in the offspring, or due to integration of the nucleic acid molecule in the host cell genome.

[0177] The term "expression" as used herein refers to the biosynthesis of a gene product. This term includes the transcription of a gene into RNA. The term also includes the translation of RNA into one or more polypeptides, and further includes all naturally occurring post-transcriptional and post-translational modifications. The expressed antibody may be present in the cytoplasm of the host cell, enter the extracellular environment (e.g., growth medium for cell culture) or be fixed on the cell membrane.

[0178] As used herein, the terms "peptide", "polypeptide" or "protein" may refer to molecules composed of amino acids and may be recognized as proteins by those skilled in the art. Conventional single-letter or three-letter amino acid residue codes are used herein. The terms "peptide", "polypeptide" and "protein" are used interchangeably herein to refer to amino acid polymers of any length. The polymer may be linear or branched, it may contain modified amino acids, and may be interrupted by non-amino acids. The term also includes amino acid polymers modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as coupling with a labeling component. This definition also includes, for example, polypeptides containing one or more amino acid analogs (including, for example, non-natural amino acids, etc.), as well as other modifications known in the art.

[0179] The peptide sequences described herein are written according to the general convention, wherein the N-terminal region of the peptide is on the left and the C-terminal region is on the right. Although isomeric forms of amino acids are known, unless otherwise explicitly stated, the L-form of the amino acid is indicated.

[0180] Chimeric Antigen Receptor (CAR)

[0181] As used herein, the term "chimeric antigen receptor" (CAR) refers to a recombinant polypeptide comprising at least an extracellular domain that specifically binds to an antigen or target, a transmembrane domain, and an intracellular T cell receptor activation signaling domain. Binding of the extracellular domain of CAR to the target antigen on the surface of the target cell causes CAR aggregation and provides activation stimulation to cells containing CAR. CARs change the specificity of immune effector cells and trigger proliferation, cytokine production, phagocytosis, and / or the production of molecules that mediate the death of target antigen-expressing cells in a manner that is independent of major histocompatibility (MHC).

[0182] On the one hand, CAR includes an antigen binding domain, a hinge region, a costimulatory domain, an activation domain and a transmembrane region. On the one hand, CAR includes an antigen binding domain, a hinge region, two costimulatory domains, an activation domain and a transmembrane region. On the one hand, CAR includes two antigen binding domains, a hinge region, a costimulatory domain, an activation domain and a transmembrane region. On the one hand, CAR includes two antigen binding domains, a hinge region, two costimulatory domains, an activation domain and a transmembrane region.

[0183] As used herein, the term "signal peptide" refers to a leader sequence at the amino terminus (N terminus) of a nascent CAR protein that co-translationally or post-translationally directs the nascent protein to the endoplasmic reticulum and subsequently to surface expression.

[0184] As used herein, the term "extracellular antigen binding domain", "extracellular domain" or "extracellular ligand binding domain" refers to the portion of the CAR that is located outside the cell membrane and is capable of binding to an antigen, target or ligand.

[0185] As used herein, the term "hinge region" refers to the portion of a CAR that connects two adjacent domains of a CAR protein (e.g., an extracellular domain and a transmembrane domain).

[0186] As used herein, the term "transmembrane domain" refers to the portion of CAR that extends across the cell membrane and anchors CAR to the cell membrane. It is sometimes referred to as a "transmembrane region".

[0187] Costimulatory domain

[0188] As used herein, a chimeric antigen receptor can incorporate a co-stimulatory (signaling) domain to increase its effectiveness. The co-stimulatory (signaling) domain can be derived from a co-stimulatory molecule. A co-stimulatory molecule is a cell surface molecule other than an antigen receptor or its ligand that is necessary for an effective immune response. The co-stimulatory domain can be derived from a co-stimulatory molecule, including but not limited to CD28, CD28T, OX40, 4-1BB / CD137, CD2, CD3 (α, β, δ, ε, γ, ζ), CD4, CD5, CD7, CD9, CD16, CD22, CD27, CD30, CD33, CD37, CD40, CD45, CD64, CD80, CD86, CD134, CD137, CD154, programmed death-1 (PD-1), inducible T cell co-stimulator (ICOS), lymphocyte function-associated antigen-1 (LFA-1; CD11a and CD18), CD247, CD276 (B7-H3), LIGHT (tumor necrosis factor superfamily member 14; TNFSF14), NKG2C, Igα (CD79a), DAP10, Fcγ receptor, MHC Class I molecules, TNFR, integrin, lymphocyte activation signaling molecules, BTLA, Toll ligand receptor, ICAM-1, CDS, GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD8α, CD8β, IL-2Rβ, IL-2Rγ, IL-7Rα, ITGA4, VLA1, CD49a, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, ITGAE, CD103, ITGAL, CD1a, CD1b, CD1c, CD1d, ITGAM, ITGAX, ITGB1, CD29, ITGB2 (CD1 8), ITGB7, NKG2D, TNFR2, TRANCE / RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, ​​LAT, GADS, SLP-76, PAG / Cbp, CD19a, CD83 ligand, cytokine receptor, activating NK cell receptor or its fragment or any combination thereof.

[0189] Activation domain

[0190] As used herein, a chimeric antigen receptor may include an activation domain. The activation domain may include, but is not limited to, CD3. CD3 is a component of the T cell receptor on natural T cells and has been shown to be an important intracellular activation component in CAR. In a preferred embodiment, CD3 is CD3ζ.

[0191] Hinge area

[0192] As described herein, chimeric antigen receptors may include a hinge region. This is a portion of the extracellular domain, sometimes referred to as a "spacer". A variety of hinges may be used according to the present invention, including costimulatory molecules, immunoglobulin (Ig) sequences, or other suitable molecules as described above, to achieve a desired specific distance from a target cell. In some embodiments, the entire extracellular region includes the hinge region.

[0193] Transmembrane region

[0194] As used herein, chimeric antigen receptors (CARs) may include a transmembrane region / domain. CAR can be designed to include a transmembrane domain that is fused to the extracellular domain of CAR. Similarly, it can be fused to the intracellular region of CAR. In one embodiment, a transmembrane domain naturally associated with one of the domains in CAR is used. In some cases, the transmembrane domain can be selected or modified by amino acid substitution to avoid binding of these domains to the transmembrane domains of the same or different surface membrane proteins, thereby minimizing interactions with other members of the receptor complex. The transmembrane domain can be natural or synthetic. If the source is natural, the domain can be derived from any membrane-bound protein or transmembrane protein.The transmembrane region specifically used in the present invention can be derived from (i.e., includes or engineered from) but is not limited to: CD28, CD28T, OX40, 4-1BB / CD137, CD2, CD3 (α, β, δ, ε, γ, ζ), CD4, CD5, CD7, CD9, CD16, CD22, CD27, CD30, CD33, CD37, CD40, CD45, CD64, CD80, CD86, CD134, CD137, CD154, programmed death-1 (PD-1), induced T cell co-stimulator (ICOS), lymphocyte function-associated antigen-1 (LFA-1; CD11a and CD18), CD247, CD276 (B7-H3), LIGHT (tumor necrosis factor superfamily member 14; TNFSF14), NKG2C, Igα (CD79a), DAP10, Fcγ receptor, MHC Class I molecules, TNFR, integrin, lymphocyte activation signaling molecules, BTLA, Toll ligand receptor, ICAM-1, CDS, GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD8α, CD8β, IL-2Rβ, IL-2Rγ, IL-7Rα, ITGA4, VLA1, CD49a, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, ITGAE, CD103, ITGAL, CD1a, CD1b, CD1c, CD1d, ITGAM, ITGAX, ITGB1, CD29, ITGB2 (CD18), I TGB7, NKG2D, TNFR2, TRANCE / RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, ​​LAT, GADS, SLP-76, PAG / Cbp, CD19a, CD83 ligand, cytokine receptor, activating NK cell receptor, immunoglobulin protein or fragment, or any combination thereof.

[0195] Immune cells

[0196] In a specific aspect, the present invention provides a cell, which is an immune cell comprising an isolated polynucleotide or a vector comprising an isolated polynucleotide, wherein the isolated polynucleotide comprises a nucleotide sequence encoding the CARs of the present invention. Immune cells comprising isolated polynucleotides and / or vectors of the present invention may be referred to as "engineered immune cells". Preferably, the engineered immune cells are derived from humans (derived from humans before recombination).

[0197] For example, the engineered immune cells can be lymphoid cells. Non-limiting examples of lymphoid cells include T cells and natural killer (NK) cells. T cells express T cell receptors (TCRs), most cells express α and β chains, and a few cells express γ and δ chains. T cells that can be used as engineered immune cells of the present invention can be CD4 + or CD8 + and may include, but are not limited to, helper T cells (CD4 + ), cytotoxic T cells (also called cytotoxic T lymphocytes, CTL; CD8 + Cells) and memory T cells, including central memory T cells, stem cell-like memory T cells, effector memory T cells, natural killer T cells, mucosa-associated invariant T cells and γδT cells. Other exemplary immune cells include, but are not limited to, macrophages, antigen presenting cells (APCs), or any immune cells expressing cell-mediated immune response inhibitors, such as immune checkpoint inhibitor pathway receptors (e.g., PD-1). According to the present invention, the precursor cells of immune cells can be used including hematopoietic stem cells and / or progenitor cells. Hematopoietic stem cells and / or progenitor cells can be obtained from bone marrow, umbilical cord blood, adult peripheral blood after cytokine mobilization, etc. by methods known in the art. Immune cells are engineered into cells that recombinantly express the CAR of the present invention.

[0198] Immune cells and their precursor cells can be separated by methods known in the art, including commercially available methods (see, for example, Rowland Jones et al., Lymphocytes: A Practical Approach, Oxford University Press, New York, 1999). The sources of immune cells or their precursors include, but are not limited to, peripheral blood, umbilical cord blood, bone marrow or other hematopoietic cell sources. Various techniques can be used to separate cells to separate or enrich the desired immune cells. For example, negative selection methods can be used to remove cells of non-desired immune cells. In addition, positive selection methods can be used to separate or enrich the desired immune cells or their precursors, or a combination of positive selection methods and negative selection methods can be used. If a specific type of cell is to be separated, for example, a specific T cell, various cell surface markers or marker combinations (e.g., CD3, CD4, CD8, CD34) can be used to separate cells.

[0199] In the treatment methods of the present invention, immune cells or their precursor cells can be autologous or non-autologous relative to the subject to which they are administered. Autologous cells are isolated from the subject to whom the engineered immune cells expressing the engineered recombinant CAR are to be administered. Optionally, the cells can be obtained by leukocyte separation, where the white blood cells are selectively removed from the drawn blood, recombined, and then returned to the donor. In addition, allogeneic cells from non-autologous donors can also be used. In the case of non-autologous donors, the cells are matched with human leukocyte antigens (HLA) after typing to determine the appropriate cell compatibility of the two. For autologous and non-autologous cells, the cells can be selected for cryopreservation until ready for use.

[0200] A variety of methods have been previously described for isolating immune cells that can be used for recombinant expression of CARs of the present invention, including but not limited to: using peripheral donor lymphocytes (Sadelain et al., Nat. Rev. Cancer 2003; 3:35-45; Morgan et al., Science 2006;314:126-9); using lymphocyte cultures derived from tumor infiltrating lymphocytes (TILs) in tumor biopsies (Panelli et al., J. Immunol. 2000;164:495-504; Panelli et al., J. Immunol. 2000;164:4382-92), and using artificial antigen presenting cells (AAPCs) or dendritic cells to selectively expand antigen-specific peripheral blood leukocytes in vitro (Dupont et al., Cancer Res. 2005;65:5417-427; Papanicolaou et al., Blood 2003;102:2498-505). Where stem cells are used, the cells can be isolated by methods well known to those skilled in the art (e.g., see Klug et al., Hematopoietic Stem Cells: A Laboratory Manual, Humana Press, New Jersey 2002; Freshney et al., Cultivation of Human Stem Cells, John Wiley & Sons, 2007).

[0201] According to a specific embodiment, the method for manufacturing engineered immune cells includes transfection or transduction of immune effector cells separated from individuals, so that immune effector cells express one or more CARs according to embodiments of the present invention. The method for preparing immune cells for immunotherapy is described in, for example, WO2014 / 130635, WO2013 / 176916 and WO2013 / 176915, which are incorporated herein by reference. The various steps that can be used to prepare engineered immune cells are described in, for example, WO2014 / 039523, WO2014 / 184741, WO2014 / 191128, WO2014 / 184744 and WO2014 / 184143, which are incorporated herein by reference.

[0202] In a specific embodiment, immune effector cells, such as T cells, are genetically modified (for example, transduced with a viral vector comprising a nucleic acid encoding CAR) with the CAR of the present invention, and then activated and amplified in vitro. In various embodiments, T cells can be activated and amplified to express CAR before or after genetic modification, using methods such as US6352694, US6534055, US6905680, US6692964, US5858358, US6887466, US6905681, US7144575, US7067318, US7172869, US7232566, US7175843, US5883223, US6905874, US6797514, US6867041, US2006 / 121005, which are incorporated herein by reference. T cells can be amplified in vitro or in vivo. Typically, the T cells of the present invention can be attached with reagents that can stimulate CD3 / TCR complex-related signals and surfaces that stimulate ligands of T cell surface co-stimulatory molecules, thereby achieving T cell expansion. As a non-limiting example, T cell groups can be stimulated by a method as described herein, such as by contacting anti-CD3 antibodies or their antigen-binding fragments, or anti-CD3 antibodies fixed on the surface, or by contacting a protein kinase C activator (such as bryostatin) bound to a calcium ion carrier, or by activating CAR itself. Use a ligand that binds to an auxiliary molecule to co-stimulate the auxiliary molecules on the surface of T cells. For example, under conditions suitable for stimulating T cell proliferation, T cell groups can be contacted with anti-CD3 antibodies and anti-CD28 antibodies. Conditions suitable for T cell culture include, for example, suitable culture medium (e.g., minimal essential medium or RPMI culture medium 1640 or X-vivo 5 (Lonza)), which may contain factors required for proliferation and survival, including serum (e.g., fetal bovine or human serum), cytokines, such as IL-2, IL-7, IL-15 and / or IL-21, insulin, IFN-g, GM-CSF, TGFβ and / or any other additives for cell growth known to the skilled person. In other embodiments, the methods described in US6040177, US5827642 and WO2012129514 may be used, using feeder cells, suitable antibodies and cytokines to activate and stimulate T cell proliferation, which are incorporated herein by reference.

[0203] Antibodies and antigen binding domains

[0204] The present invention generally relates to isolated anti-mesothelin antibodies, chimeric antigen receptors (CARs), nucleic acids encoding the antibodies and CARs and expression vectors, recombinant cells containing the vectors, and compositions comprising the antibodies, CARs, and recombinant cells expressing the CARs, methods for preparing antibodies and CARs, and methods for using antibodies and CARs to treat diseases including cancer, inflammatory diseases, and autoimmune diseases. The antigen binding domains of the antibodies and CARs of the present invention have one or more desirable functional properties, including but not limited to high affinity binding to mesothelin, high specificity for mesothelin, the ability to stimulate complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP), and / or antibody-dependent cellular cytotoxicity (ADCC) against cells expressing mesothelin, and the ability to inhibit tumor growth in subjects and animal models when used alone or in combination with other anti-cancer therapies.

[0205] In general, the present invention relates to isolated monoclonal antibodies, or antigen-binding fragments thereof, that bind mesothelin.

[0206] As used herein, the term "antibody" is a broad antibody, including immunoglobulins or antibody molecules, including monoclonal or polyclonal human, humanized, composite and chimeric antibodies and antibody fragments. In general, antibodies are proteins or peptide chains that have binding specificity to specific antigens. The structure of antibodies is well known. According to the different amino acid sequences of the heavy chain constant domain, immunoglobulins can be divided into five major categories (IgA, IgD, IgE, IgG and IgM). IgA and IgG can be further subdivided into several subtypes IgA1, IgA2, IgG1, IgG2, IgG3 and IgG4. Accordingly, the antibodies of the present invention can be any of the above five major categories or corresponding subtypes. Preferably, the antibodies of the present invention are IgG1, IgG2, IgG3 or IgG4. Based on the amino acid sequence of the constant domain, the antibody light chains of vertebrates can be divided into two distinct types, κ and λ lambda. Therefore, the antibodies of the present invention may contain κ or λ light chain constant domains. According to a specific embodiment, the antibodies of the present invention include heavy chain and / or light chain constant regions from rat or human antibodies. In addition to the heavy and light chain constant domains, antibodies also contain an antigen binding region, which is composed of a light chain variable region and a heavy chain variable region, each of which contains three domains (i.e., complementary determining regions 1-3; CDR1, CDR2, CDR3). The light chain variable regions can be referred to as LCDR1, LCDR2, and LCDR3, respectively, and the heavy chain variable regions can be referred to as HCDR1, HCDR2, and HCDR3, respectively.

[0207] "Complementarity determining region" (CDR) is the region of an antibody that binds to an antigen. CDRs can be defined by a variety of methods, such as Kabat (Wu et al., J Exp Med 132:211-50, 1970) (Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, Maryland, 1991), Chothia (Chothia et al., J Mol Biol 196:901-17, 1987), IMGT (Lefranc et al., Dev Comp Immunol 27:55-77, 2003) and AbM (Martin and Thornton J Bmol Biol 263:800-15, 1996). The correspondence between the various definitions and the description of the variable region numbering are as follows, (e.g., see Lefranc et al., Dev Comp Immunol 27:55-77, 2003; Honegger and Pluckthun, J Mol Biol 309:657-70, 2001; International ImMunoGeneTics (IMGT) database; web resource, http: / / www_imgt_org). Programs that can be used to define CDRs, such as abYsis of UCL Business PLC (UCL Business PLC). Unless otherwise expressly provided in this specification, the terms "CDR", "HCDR1", "HCDR2", "HCDR3", "LCDR1", "LCDR2" and "LCDR3" used herein include CDRs defined in any of the above methods (Kabat, Chothia, IMGT or AbM). Those skilled in the art are familiar with the correspondence between different numbering systems, including, for example, the Kabat numbering system and the IMGT special numbering system. (See, e.g., Kabat; Chothia; Martin; Lefranc et al.).

[0208] Table A. Definition of CDR by different methods

[0209]

[0210]

[0211] As used herein, the term "isolated antibody" refers to an antibody that is substantially free of other antibodies with different antigenic specificities (e.g., an isolated antibody that specifically binds to mesothelin is substantially free of antibodies that do not bind to mesothelin). In addition, an isolated antibody is substantially free of other cellular material and / or chemicals.

[0212] As used herein, the term "monoclonal antibody" refers to an antibody obtained from a substantially homologous antibody population, i.e., the individual antibodies in the antibody population are identical except for possible natural mutations that may be present in small amounts. The monoclonal antibodies of the present invention can be prepared by hybridoma methods, phage display technology, single lymphocyte gene cloning technology, or recombinant DNA methods. For example, monoclonal antibodies can be produced by hybridomas comprising B cells obtained from transgenic non-human animals (e.g., transgenic mice or rats) comprising genomes of human heavy chain transgenes and light chain transgenes.

[0213] As used herein, the term "antigen binding fragment" and / or "antigen binding domain" refers to an antibody fragment, such as a diabody, Fab, Fab', F(ab')2, an Fv fragment, a disulfide-stabilized Fv fragment (dsFv), (dsFv)2, a bispecific dsFv (dsFv-dsFv'), a disulfide-stabilized diabody (ds diabody), a single-chain antibody molecule (scFv), a single-domain antibody (sdab) and a scFv dimer (a bivalent diabody), a multispecific antibody formed by a portion of an antibody comprising one or more CDRs, a camelid single-domain antibody, a nanobody, a domain antibody, a bivalent domain antibody, or any other antibody fragment that binds to an antigen but does not contain a complete antibody structure. An antigen binding fragment is capable of binding to the same antigen to which a parent antibody or parent antibody fragment binds. According to a specific embodiment, the antigen binding fragment comprises a light chain variable region, a light chain constant region, and a heavy chain Fd segment. According to other specific embodiments, the antigen binding fragment comprises Fab and F(ab'). The antigen binding domain is capable of binding to the same antigen that the parent antibody binds. According to a specific embodiment, the antigen binding domain comprises a single chain antibody molecule (scFv).

[0214] As used herein, the term "single-chain antibody" refers to a conventional single-chain antibody in the art, which includes a heavy chain variable region and a light chain variable region connected by a short peptide of about 15-20 amino acids. As used herein, the term "single-domain antibody" refers to a conventional single-domain antibody in the art, which includes a heavy chain variable region and a heavy chain constant region or only includes a heavy chain variable region.

[0215] As used herein, the term "human antibody" refers to an antibody produced by a human or an antibody prepared using any technique known in the art having a specific amino acid sequence corresponding to an antibody produced by a human. The definition of a human antibody includes complete or full-length antibodies, fragments thereof, and / or antibodies comprising at least one human heavy chain and / or light chain polypeptide.

[0216] As used herein, the terms "humanized antibody" and / or "humanized antigen-binding domain" refer to a non-human antibody and / or a non-human antigen-binding domain that has been modified to increase its sequence homology to a human antibody and / or a human antigen-binding domain so as to render it less antigenic in humans while retaining the antigen-binding properties of the antibody and / or antigen-binding domain.

[0217] As used herein, the term "chimeric antibody" and / or "chimeric antigen binding domain" refers to an antibody and / or an immunoglobulin molecule in which the amino acid sequence is derived from two or more species. The variable regions of the light and heavy chains usually correspond to the variable regions of an antibody and / or antigen binding domain from one mammal (such as mouse, rat, rabbit, etc.) with the desired specificity, affinity and capacity, while the constant region corresponds to the sequence of an antibody and / or antigen binding domain from another mammal (such as human) to avoid causing an immune response in that species.

[0218] As used herein, the term "multispecific antibody" refers to an antibody comprising multiple immunoglobulin variable domain sequences, wherein a first immunoglobulin variable domain sequence specifically binds to a first epitope, and a second immunoglobulin variable domain sequence specifically binds to a second epitope. In one embodiment, the first and second epitopes are located on the same antigen, for example, the same protein (or subunit of a multimeric protein). In one embodiment, the first and second epitopes overlap or substantially overlap. In one embodiment, the first and second epitopes do not overlap or substantially do not overlap. In one embodiment, the first and second epitopes are located on different antigens, for example, different proteins (or different subunits of a multimeric protein). In one embodiment, the multispecific antibody comprises a third, fourth or fifth immunoglobulin variable domain. In one embodiment, the multispecific antibody is a bispecific antibody molecule, a trispecific antibody molecule or a tetraspecific antibody molecule.

[0219] As used herein, the term "bispecific antibody" refers to a multispecific antibody that binds no more than two epitopes or two antigens. A bispecific antibody is characterized in that it has a first immunoglobulin variable domain sequence that specifically binds to a first epitope and a second immunoglobulin variable domain sequence that specifically binds to a second epitope. In one embodiment, the first and second epitopes are located on the same antigen, for example, the same protein (or subunit of a multimeric protein). In one embodiment, the first and second epitopes overlap or substantially overlap. In one embodiment, the first and second epitopes are located on different antigens, for example, different proteins (or different subunits of a multimeric protein). In one embodiment, a bispecific antibody includes a heavy chain variable domain sequence and a light chain variable domain sequence that specifically bind to a first epitope, and a heavy chain variable domain sequence and a light chain variable domain sequence that specifically bind to a second epitope. In one embodiment, a bispecific antibody includes a half antibody or a fragment thereof that specifically binds to a first epitope and a half antibody or a fragment thereof that specifically binds to a second epitope. In one embodiment, a bispecific antibody includes a scFv or a fragment thereof that specifically binds to a first epitope, and a scFv or a fragment thereof that specifically binds to a second epitope. In one embodiment, the first epitope is located on the mesothelin of the present invention, and the second epitope is located on PD-1, PD-L1, TIM-3, LAG-3, CTLA-4, EGFR, HER-2, CD19, CD20, CD33, CD3, CD73, CD47, TIP-1, GPC3, apelin, DLL3, folate receptor α, Claudin 18.2, MUC16, 5T4, IL13Ra2, PSCA, EGFRvIII, p95HER2, ROR1, ROR2, NKp46 and / or other tumor-associated immunosuppressive factors or surface antigens. In one embodiment, the first and second epitopes are located on the same mesothelin of the present invention.

[0220] As used herein, an antibody and / or antigen binding domain that "specifically binds to mesothelin" refers to an antibody and / or antigen binding domain that specifically binds to mesothelin at a concentration of 1×10 -7 M or less, preferably 1×10 -8 M or less, more preferably 5×10 -9 M or smaller, 1×10 -9 M or smaller, 5×10 -10 M or smaller, or 1×10 -10The term "KD" refers to the dissociation constant, which is obtained by the ratio of Kd to Ka (i.e., Kd / Ka) and is expressed as a molar concentration (M). In the present invention, the KD value of the antibody and / or antigen binding domain can be determined using methods in the art. For example, the KD value of the antibody and / or antigen binding domain can be determined using surface plasmon resonance, such as using a biosensor system, such as systems, or using bio-layer interferometry techniques, such as the Octet RED96 system.

[0221] The smaller the KD value of the antibody and / or antigen binding domain, the higher the affinity of the antibody and / or antigen binding domain to the target antigen.

[0222] As used herein, the term "IC50" refers to the half-maximal inhibitory concentration of a monoclonal or bispecific antibody or antigen-binding fragment thereof of the invention. IC50 is an indicator for evaluating the inhibitory ability of a monoclonal or bispecific antibody or antigen-binding fragment thereof of the invention, inhibiting the binding of a target antigen (i.e., a receptor or ligand) to its natural ligand or receptor, or inhibiting the function of a target antigen in a cell. In certain embodiments, the KD of a monoclonal antibody or antigen-binding fragment thereof, or a bispecific antibody or antigen-binding fragment thereof, is less than about 10 -7 M, less than about 10 -8 M, less than about 10 -9 M, less than about 10 -10 M, less than about 10 -11 M, less than about 10 -12 M or less than about 10 -13 M.

[0223] As used herein, the term "EC50" refers to the half-maximal effective concentration of a monoclonal or bispecific antibody or its antigen-binding fragment of the invention. EC50 refers to the half-maximal concentration between the baseline and the maximum value of a monoclonal or bispecific antibody or its antigen-binding fragment that induces a biological response (i.e., cell death) during a specific exposure time. In a specific embodiment, the EC50 of a monoclonal antibody or its antigen-binding fragment or a bispecific antibody or its antigen-binding fragment is less than about 1 μM, about 1000 nM to about 100 nM, about 100 nM to about 10 nM, about 10 nM to about 1 nM, about 1000 pM to about 500 pM, about 500 pM to about 200 pM, less than about 200 pM, about 200 pM to about 150 pM, about 200 pM to about 100 pM, about 100 pM to about 10 pM, or about 10 pM to about 1 pM.

[0224] Specifically, the present invention relates to an isolated monoclonal antibody or an antigen-binding fragment thereof or a chimeric antigen receptor (CAR) comprising an antigen-binding domain, wherein the monoclonal antibody or its antigen-binding fragment or antigen-binding domain comprises a heavy chain variable region, which comprises a heavy chain complementary determining region 1 (HCDR1), HCDR2, HCDR3; and a light chain variable region, which comprises a light chain complementary determining region 1 (LCDR1), LCDR2 and LCDR3, which respectively have the following polypeptide sequences:

[0225] (1) SEQ ID NO: 3, 4, 5, 6, 7 and 8, or SEQ ID NO: 9, 10, 11, 12, 13 and 14;

[0226] (2) SEQ ID NOs: 17, 18, 19, 20, 21 and 22, or SEQ ID NOs: 23, 24, 25, 26, 27 and 28;

[0227] (3) SEQ ID NOs: 31, 32, 33, 34, 35 and 36, or SEQ ID NOs: 37, 38, 39, 40, 41 and 42;

[0228] (4) SEQ ID NOs: 60, 61, 62, 63, 64 and 65, or SEQ ID NOs: 66, 67, 68, 69, 70 and 71;

[0229] Wherein, the antibody or antigen-binding fragment thereof or antigen-binding domain thereof specifically binds to mesothelin, preferably human mesothelin.

[0230] In another specific aspect, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof, or a chimeric antigen receptor (CAR) comprising an antigen-binding domain, wherein the monoclonal antibody or antigen-binding fragment thereof, or the antigen-binding domain comprises a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or more (e.g., 95%, 96%, 97%, 98%, 99%) identical to one of SEQ ID NOs: 1, 15, 29 or 58; or comprises a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or more (e.g., 95%, 96%, 97%, 98%, 99%) identical to SEQ ID NOs: 2, 16, 30 or 59. In another preferred embodiment, the monoclonal antibody or antigen-binding fragment thereof or antigen-binding domain thereof of the present invention comprises a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher (e.g., 95%, 96%, 97%, 98%, 99%) identical to SEQ ID NO: 1, 15, 29 or 58; and a light chain variable region having a polypeptide sequence that is at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 2, 16, 30 or 59.

[0231] In another specific aspect, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof or antigen-binding domain thereof, comprising:

[0232] (1) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 1 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 2;

[0233] (2) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 15 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 16;

[0234] (3) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 29 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 30; or

[0235] (4) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 58 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 59.

[0236] In one embodiment, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof, which comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, which respectively have the polypeptide sequences of SEQ ID NOs: 3, 4, 5, 6, 7 and 8 or SEQ ID NOs: 9, 10, 11, 12, 13 and 14. In another embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher (e.g. 95%, 96%, 97%, 98%, 99%) identical to SEQ ID NO: 1; and a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher (e.g. 95%, 96%, 97%, 98%, 99%) identical to SEQ ID NO: 2. Preferably, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 1; and a light chain variable region having a polypeptide sequence of SEQ ID NO: 2.

[0237] In one embodiment, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof, which comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, which have the polypeptide sequences of SEQ ID NOs: 17, 18, 19, 20, 21 and 22 or SEQ ID NOs: 23, 24, 25, 26, 2 and 28, respectively. In another embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher (e.g., 95%, 96%, 97%, 98%, 99%) identical to SEQ ID NO: 15; and a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher (e.g., 95%, 96%, 97%, 98%, 99%) identical to SEQ ID NO: 16. Preferably, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence of SEQ ID NO:15; and a light chain variable region having a polypeptide sequence of SEQ ID NO:16.

[0238] In one embodiment, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof, which comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, which have the polypeptide sequences of SEQ ID NO:31, 32, 33, 34, 35 and 36 or SEQ ID NO:37, 38, 39, 40, 41 and 42, respectively. In another embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher (e.g., 95%, 96%, 97%, 98%, 99%) identical to SEQ ID NO:29; and a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher (e.g., 95%, 96%, 97%, 98%, 99%) identical to SEQ ID NO:30. Preferably, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 29; and a light chain variable region having a polypeptide sequence of SEQ ID NO: 30.

[0239] In one embodiment, the present invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof, which comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, which respectively have the polypeptide sequences of SEQ ID NOs: 60, 61, 62, 63, 64 and 65 or SEQ ID NOs: 66, 67, 68, 69, 70, 71. In another embodiment, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher (e.g., 95%, 96%, 97%, 98%, 99%) identical to SEQ ID NO: 58; and a light chain variable region having a polypeptide sequence that is at least 85%, preferably 90%, more preferably 95% or higher (e.g., 95%, 96%, 97%, 98%, 99%) identical to SEQ ID NO: 59. Preferably, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region having a polypeptide sequence of SEQ ID NO:58; and a light chain variable region having a polypeptide sequence of SEQ ID NO:59.

[0240] In another specific aspect, the invention relates to an isolated monoclonal antibody or antigen-binding fragment or antigen-binding domain thereof, wherein the antibody or antigen-binding fragment or antigen-binding domain thereof is chimeric.

[0241] In another specific aspect, the invention relates to an isolated monoclonal antibody or antigen-binding fragment or antigen-binding domain thereof, wherein the antibody or antigen-binding fragment or antigen-binding domain thereof is human or humanized.

[0242] In another specific aspect, the humanized monoclonal antibody or antigen-binding fragment thereof or a humanized antigen-binding domain comprises a heavy chain variable region having a polypeptide sequence that is at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to any one of SEQ ID NOs: 43-46, 52-55 or 72-75, or a light chain variable region having a polypeptide sequence that is at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to any one of SEQ ID NOs: 47-51, 56-57 or 76-78.

[0243] In another specific aspect, the humanized monoclonal antibody or antigen-binding fragment thereof or humanized antigen-binding domain comprises:

[0244] (1) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 43 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 47;

[0245] (2) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 43 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 48;

[0246] (3) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 43 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 49;

[0247] (4) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 43 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 50;

[0248] (5) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 43 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 51;

[0249] (6) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 44 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 47;

[0250] (7) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 44 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 48;

[0251] (8) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 44 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 49;

[0252] (9) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 44 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 50;

[0253] (10) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 44 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 51;

[0254] (11) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 45 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 47;

[0255] (12) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 45 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 48;

[0256] (13) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 45 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 49;

[0257] (14) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 45 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 50;

[0258] (15) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 45 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 51;

[0259] (16) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 46 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 47;

[0260] (17) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 46 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 48;

[0261] (18) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 46 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 49;

[0262] (19) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 46 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 50;

[0263] (20) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 46 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 51;

[0264] (21) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 52 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 56;

[0265] (22) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 52 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 57;

[0266] (23) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 53 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 56;

[0267] (24) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 53 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 57;

[0268] (25) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 54 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 56;

[0269] (26) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 54 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 57;

[0270] (27) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 55 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 56;

[0271] (28) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 55 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 57;

[0272] (29) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 72 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 76;

[0273] (30) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 72 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 77;

[0274] (31) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 72 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 78;

[0275] (32) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 73 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 76;

[0276] (33) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 73 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 77;

[0277] (34) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 73 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 78;

[0278] (35) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 74 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 76;

[0279] (36) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 74 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 77;

[0280] (37) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 74 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 78;

[0281] (38) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 75 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 76;

[0282] (39) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 75 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 77; or

[0283] (40) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 75 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 78.

[0284] In another specific aspect, the antigen binding domain is a single chain variable fragment (scFv).

[0285] In certain embodiments, the encoded antigen binding domain is a humanized single chain variable fragment (scFv).

[0286] In another specific aspect, a chimeric antigen receptor (CAR) comprises one or more antigen binding domains.

[0287] In another specific aspect, the intracellular signaling domain comprises one or more co-stimulatory domains and one or more activation domains.

[0288] In another general aspect, the present invention relates to an isolated nucleic acid encoding a monoclonal antibody or its antigen-binding fragment and / or a bispecific antibody or its antigen-binding fragment of the present invention. In another basic aspect, the present invention relates to an isolated polynucleotide comprising a nucleic acid encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen-binding domain of the present invention. It will be appreciated by those skilled in the art that the coding sequence of the protein can be changed (e.g., replaced, deleted, inserted, etc.) without changing the amino acid sequence of the protein. Therefore, it will be appreciated by those skilled in the art that the nucleic acid sequence encoding the monoclonal antibody or its antigen-binding fragment of the present invention can be changed without changing the amino acid sequence of the protein.

[0289] In another general aspect, the present invention relates to a vector comprising an isolated nucleic acid encoding a monoclonal antibody or its antigen-binding fragment, a bispecific antibody or its antigen-binding fragment and / or a CAR of the present invention. Based on the present invention, those skilled in the art may use any known vector, such as a plasmid, a cosmid, a phage vector or a viral vector. In some embodiments, the vector is a recombinant expression vector, such as a plasmid. The vector may include any elements for establishing the conventional functions of the expression vector, such as a promoter, a ribosome binding element, a terminator, an enhancer, a selection marker, and an origin of replication. The promoter may be a constitutive, inducible or repressible promoter. Many expression vectors known in the art capable of delivering nucleic acids to cells can be used to produce antibodies or their antigen-binding fragments in cells. Conventional cloning techniques or artificial gene synthesis can be used to produce recombinant expression vectors according to embodiments of the present invention.

[0290] Another general aspect, the present invention relates to a host cell, the host cell comprising a nucleic acid encoding a monoclonal antibody or its antigen-binding fragment of the present invention and / or its bispecific antibody or its antigen-binding fragment. Based on the present invention, those skilled in the art can use any known host cell to recombinantly express the antibody or its antigen-binding fragment of the present invention. In some embodiments, the host cell is an Escherichia coli TG1 or BL21 cell (for expression, for example, scFv or Fab antibody), a CHO-DG44 or CHO-K1 cell or a HEK293 cell (for expression, for example, full-length IgG antibody). According to a specific embodiment, the recombinant expression vector is converted into a host cell by conventional methods such as chemical transfection, heat shock or electroporation, wherein the recombinant vector is stably integrated into the host cell genome, thereby effectively expressing the recombinant nucleic acid.

[0291] In another general aspect, the present invention relates to a method for preparing a monoclonal antibody or antigen-binding fragment thereof and / or a bispecific antibody or antigen-binding fragment thereof of the present invention, comprising: culturing a cell comprising a nucleic acid encoding the monoclonal antibody or antigen-binding fragment thereof or bispecific antibody or antigen-binding fragment thereof under conditions for preparing the monoclonal antibody or antigen-binding fragment thereof or bispecific antibody or antigen-binding fragment thereof of the present invention, and recovering the antibody or antigen-binding fragment thereof from the cell or cell culture (e.g., from the supernatant). The expressed antibody or antigen-binding fragment thereof can be harvested from the cell and purified according to conventional techniques known in the art and described herein.

[0292] In another general aspect, the present invention relates to a cell for transducing a vector comprising an isolated nucleic acid encoding a CAR of the present invention. The term "transfection" or "transduction" refers to the process by which an exogenous nucleic acid is transferred or introduced into a host cell. A "transduced" cell refers to a cell transduced with an exogenous nucleic acid. Cells include primary subject cells and their progeny. In certain embodiments, the cell is a CAR-T cell, preferably a human CAR-T cell, wherein the T cell is engineered to express a CAR of the present invention to treat a disease such as cancer. In certain embodiments, the cell is a CAR-NK cell, preferably a human CAR-NK cell, wherein the NK cell is engineered to express a CAR of the present invention to treat a disease such as cancer.

[0293] In another general aspect, the present invention relates to a method for making CAR-T cells by transducing T cells using a vector comprising an isolated nucleic acid encoding the CAR of the present invention.

[0294] In another general aspect, the present invention relates to a method for preparing the CAR-T cells of the present invention, comprising culturing T cells containing a nucleic acid encoding a chimeric antigen receptor (CAR) of the present invention under conditions for preparing the CAR-T cells of the present invention, and recovering the CAR-T cells.

[0295] In another general aspect, the present invention relates to a method of making CAR-NK cells by transducing NK cells using a vector comprising an isolated nucleic acid encoding the CARs of the present invention.

[0296] In another general aspect, the present invention relates to a method for preparing the CAR-NK cells of the present invention, comprising culturing NK cells containing a nucleic acid encoding a chimeric antigen receptor (CAR) of the present invention under conditions for preparing CAR-NK cells, and recovering the CAR-NK cells.

[0297] Another general aspect, the present invention relates to a method for preparing an RNA engineering cell group, the RNA engineering cell group comprising a chimeric antigen receptor (CAR) of the present invention. The method includes contacting a cell group with an isolated polynucleotide, the isolated polynucleotide comprising a nucleic acid encoding a CAR of the present invention, and being an in vitro transcribed RNA or a synthetic RNA.

[0298] Pharmaceutical composition

[0299] In another general aspect, the present invention relates to a pharmaceutical composition comprising an isolated monoclonal antibody or antigen-binding fragment thereof, a bispecific antibody or antigen-binding fragment thereof, an isolated polynucleotide, an isolated polypeptide, a host cell and / or an engineered immune cell, and a pharmaceutically acceptable carrier of the present invention.

[0300] The term "pharmaceutical composition" as used herein refers to a product comprising the isolated polynucleotide, isolated polypeptide, host cell, engineered immune cell, anti-mesothelin monoclonal antibody or antigen-binding fragment thereof and / or bispecific antibody of the present invention, and a pharmaceutically acceptable carrier. The polynucleotide, polypeptide, host cell, engineered immune cell, anti-mesothelin monoclonal antibody or antigen-binding fragment thereof and / or bispecific antibody and compositions comprising the same as used herein can also be used to prepare a medicament for the therapeutic applications described herein.

[0301] As used herein, the term "carrier" refers to any excipient, diluent, filler, salt, buffer, stabilizer, solubilizer, oil, lipid, lipid-containing vesicle, microsphere, liposome encapsulation or other materials well known in the art for pharmaceutical preparations. It should be understood that the characteristics of the carrier, excipient or diluent will depend on the route of administration for a specific application. As used herein, the term "pharmaceutically acceptable carrier" refers to a non-toxic material that does not interfere with the effectiveness or biological activity of the composition as described in the present invention. According to a specific embodiment, based on the present invention, any pharmaceutically acceptable carrier suitable for antibody drug compositions can be used in the present invention.

[0302] The compatibility of active pharmaceutical ingredients with pharmaceutically acceptable carriers is a well-known technique in the art, such as Remington: Pharmacy and Practice (e.g., 21st edition (2005) and any subsequent editions). Non-limiting examples of additional ingredients include buffers, diluents, solvents, osmotic regulators, preservatives, stabilizers, and chelating agents. The pharmaceutical composition of the present invention can be prepared using one or more pharmaceutically acceptable carriers.

[0303] In one embodiment of the present invention, the pharmaceutical composition is a liquid preparation. A preferred example of a liquid preparation is an aqueous preparation, i.e., a preparation containing water. The liquid preparation may include a solution, a suspension, an emulsion, a microemulsion, a gel, etc. The aqueous preparation generally includes at least 50% w / w water, or at least 60%, 70%, 75%, 80%, 85%, 90% or at least 95% w / w water.

[0304] In one embodiment, the pharmaceutical composition can be formulated as an injectable injection form, for example, by injection through an injection device (e.g., a syringe or an infusion pump). For example, the injection can be administered subcutaneously, intramuscularly, intraperitoneally, intravitreally or intravenously.

[0305] In another embodiment, the pharmaceutical composition is a solid preparation, for example, a freeze-dried or spray-dried composition, which can be used directly, or a doctor or patient can add a solvent and / or diluent thereto before use. Solid dosage forms can include tablets, such as compressed tablets and / or coated tablets and capsules (such as hard or soft gelatin capsules). The pharmaceutical composition can also be in the form of, for example, a sachet, dragee, powder, granules, lozenge or reconstituted powder.

[0306] Dosage forms may be immediate release, in which case they may contain a water soluble or dispersible carrier; or may be delayed, sustained or modified release, in which case they may contain a water-insoluble polymer which modulates the rate at which the dosage form dissolves in the gastrointestinal tract or under the skin.

[0307] In other embodiments, the pharmaceutical composition may be delivered nasally, orally, or sublingually.

[0308] The pH in the aqueous formulation may be between pH 3 and pH 10. In one embodiment of the invention, the pH of the formulation is from about 7.0 to about 9.5. In another embodiment of the invention, the pH of the formulation is from about 3.0 to about 7.0.

[0309] In another embodiment of the present invention, the pharmaceutical composition includes a buffer. The non-limiting example of a buffer includes: arginine, aspartic acid, diglycine, citric acid, sodium dihydrogen phosphate, fumaric acid, glycine, glycine, histidine, lysine, maleic acid, malic acid, sodium acetate, sodium carbonate, sodium dihydrogen phosphate, sodium phosphate, succinic acid, tartaric acid, trimethylglycine and tris (hydroxymethyl)-aminomethane and mixtures thereof. The buffer can be present in a concentration of about 0.01mg / ml to about 50mg / ml alone or in total, for example, about 0.1mg / ml to about 20mg / ml. The pharmaceutical composition comprising any of the above-mentioned specific buffers constitutes an optional embodiment of the present invention.

[0310] In another embodiment of the present invention, the pharmaceutical composition comprises an antiseptic. The non-limiting example of antiseptic comprises: benzoic acid, benzyl alcohol, bromophenol, butyl 4-hydroxybenzoate, chlorobutanol, chlorocresol, chlorhexidine, chlorphenesin, o-cresol, meta-cresol, p-cresol, ethyl 4-hydroxybenzoate, imidourea, methyl 4-hydroxybenzoate, phenol, 2-phenoxyethanol, 2-phenylethanol, propyl 4-hydroxybenzoate, sodium dehydroacetate, thimerosal and mixture thereof. The antiseptic can exist with a concentration of about 0.01mg / ml to about 50mg / ml alone or in total, for example, about 0.1mg / ml to about 20mg / ml. The pharmaceutical composition containing any of the above-mentioned specific antiseptics constitutes an optional embodiment of the present invention.

[0311] In another embodiment of the present invention, the pharmaceutical composition includes an isotonic agent. Non-limiting examples of isotonic agents include: salts (e.g., sodium chloride), amino acids (e.g., glycine, histidine, arginine, lysine, isoleucine, aspartic acid, tryptophan, and threonine), alditols (e.g., glycerol, 1,2-propylene glycol propylene glycol, 1,3-propylene glycol, and 1,3-butylene glycol), polyethylene glycols (e.g., PEG400) and mixtures thereof. Another example of an isotonic agent includes sugar. Non-limiting examples of sugars may be monosaccharides, disaccharides, or polysaccharides, or water-soluble glucans, including, for example, fructose, glucose, mannose, sorbose, xylose, maltose, lactose, sucrose, trehalose, dextran, pullulan, dextrin, cyclodextrin, α and β-HPCD, soluble starch, hydroxyethyl starch, and sodium carboxymethylcellulose. Another example of an isotonic agent is sugar alcohol, wherein the term "sugar alcohol" is defined as a C (4-8) hydrocarbon having at least one -OH group. The example of non-limiting sugar alcohol comprises mannitol, sorbitol, inositol, galactitol, sweet alcohol, xylitol and arabitol.Isotonic agent can exist with the concentration of about 0.01mg / ml to about 50mg / ml separately or in total, for example about 0.1mg / ml to about 20mg / ml.The pharmaceutical composition comprising above-mentioned arbitrary specific isotonic agent constitutes optional embodiment of the present invention.

[0312] In another embodiment of the present invention, the pharmaceutical composition comprises a chelating agent. Non-limiting examples of chelating agents include citric acid, aspartic acid, ethylenediaminetetraacetic acid (EDTA) salts and mixtures thereof. The chelating agent may be present in a concentration of about 0.01 mg / ml to about 50 mg / ml, for example about 0.1 mg / ml to about 20 mg / ml, alone or in total. Pharmaceutical compositions comprising any of the above-mentioned specific chelating agents constitute optional embodiments of the present invention.

[0313] In another embodiment of the present invention, the pharmaceutical composition includes a stabilizer. Non-limiting examples of stabilizers include one or more aggregation inhibitors, one or more oxidation inhibitors, one or more surfactants and / or one or more protease inhibitors.

[0314] In another embodiment of the present invention, the pharmaceutical composition includes a stabilizer, wherein the stabilizer is carboxyl / hydroxycellulose and its derivatives (such as HPC, HPC-SL, HPC-1 and HPMC), cyclodextrin, 2-methylthioethanol, polyethylene glycol (such as PEG 3350), polyvinyl alcohol (PVA), polyvinyl pyridone, salt (such as sodium chloride), sulfur-containing substances (such as monothioglyceride or thioglycolic acid). The stabilizer can be present in a concentration of about 0.01 mg / ml to about 50 mg / ml, such as about 0.1 mg / ml to about 20 mg / ml, alone or in total. The pharmaceutical composition containing any of the above-mentioned specific stabilizers constitutes an optional embodiment of the present invention.

[0315] In a further embodiment of the present invention, the pharmaceutical composition includes one or more surfactants, preferably a surfactant, at least one surfactant or two different surfactants. The term "surfactant" refers to any molecule or ion composed of a water-soluble (hydrophilic) part and a fat-soluble (lipophilic) part. For example, the surfactant can be selected from anionic surfactants, cationic surfactants, nonionic surfactants and / or zwitterionic surfactants. Surfactants can exist in a concentration of about 0.1mg / ml to about 20mg / ml alone or in total. The pharmaceutical composition containing any of the above-mentioned surfactants constitutes an optional embodiment of the present invention.

[0316] In another embodiment of the present invention, the pharmaceutical composition includes one or more protease inhibitors, such as EDTA and / or benzamidine hydrochloric acid (HCl). The protease inhibitors can be present in a concentration of about 0.1 mg / ml to about 20 mg / ml alone or in total. Pharmaceutical compositions comprising any of the above-mentioned specific protease inhibitors constitute optional embodiments of the present invention.

[0317] In another aspect, the present invention relates to a method for producing a pharmaceutical composition comprising the monoclonal antibody or antigen-binding fragment thereof and / or the bispecific antibody or antigen-binding fragment thereof of the present invention, the method comprising combining the monoclonal antibody or antigen-binding fragment thereof and / or the bispecific antibody or antigen-binding fragment thereof with a pharmaceutically acceptable carrier to obtain the pharmaceutical composition.

[0318] How to use

[0319] In another general aspect, the present invention relates to a method for targeting mesothelin on the surface of cancer cells in a subject to achieve cell killing, the method comprising administering to the subject an isolated monoclonal antibody or antigen binding fragment thereof and / or a bispecific antibody or antigen binding fragment thereof that specifically binds to mesothelin of the present invention; or administering a pharmaceutical composition comprising the isolated monoclonal antibody or antigen binding fragment thereof and / or a bispecific antibody or antigen binding fragment thereof. The binding of a mesothelin monoclonal or bispecific antibody or antigen binding fragment to mesothelin can mediate complement dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP), and / or antibody-dependent cellular cytotoxicity (ADCC), or other effects that lead to the death of target cancer cells. For example, a monoclonal or bispecific antibody or an antigen binding fragment thereof can be used to recruit a conjugated drug, and / or can form a bispecific antibody with another monoclonal antibody to mediate the death of target cancer cells.

[0320] The functional activity of antibodies and antigen-binding fragments thereof that bind to mesothelin can be characterized by methods known in the art and described herein. Methods for characterizing antibodies and antigen-binding fragments thereof that bind to mesothelin include, but are not limited to, affinity and specificity analysis, including Biacore, ELISA, and OctetRed analysis, and detection of binding of antibodies and antigen-binding fragments to mesothelin on the surface of cells (cells transfected with mesothelin or cells naturally expressing mesothelin) by FACS. According to a specific embodiment, the method for characterizing antibodies and antigen-binding fragments thereof that bind to mesothelin includes the method described below.

[0321] On the other hand, the present invention relates to a method for treating cancer in a subject in need thereof, comprising administering to the subject an isolated monoclonal antibody or antigen-binding fragment thereof and / or a bispecific antibody or antigen-binding fragment thereof or a pharmaceutical composition of the present invention that specifically binds to mesothelin. The cancer may be selected from, but is not limited to, for example, lung cancer, gastric cancer, esophageal cancer, bile duct cancer, cholangiocarcinoma, cholangiocellular liver cancer, colon cancer, hepatocellular carcinoma, renal cell carcinoma, bladder urothelial carcinoma, metastatic melanoma, breast cancer, ovarian cancer, cervical cancer, head and neck cancer, pancreatic cancer, glioma, glioblastoma, mesothelioma and other solid tumors; and non-Hodgkin's lymphoma (NHL), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), multiple myeloma (MM), acute myeloid leukemia (AML) and other liquid tumors.

[0322] In another aspect, the invention relates to a method of treating an inflammatory and / or autoimmune disease in a subject in need thereof, comprising administering to the subject an isolated monoclonal antibody or antigen-binding fragment thereof and / or a bispecific antibody or antigen-binding fragment thereof or a pharmaceutical composition of the invention that specifically binds to mesothelin.

[0323] On the other hand, the present invention relates to a method for treating cancer in a subject in need, including administering the CAR-T cells and / or CAR-NK cells of the present invention to the subject. The cancer may be selected from, but not limited to, such as lung cancer, gastric cancer, esophageal cancer, bile duct cancer, cholangiocarcinoma, cholangiocellular liver cancer, colon cancer, hepatocellular carcinoma, renal cell carcinoma, bladder urothelial carcinoma, metastatic melanoma, breast cancer, ovarian cancer, cervical cancer, head and neck cancer, pancreatic cancer, glioma, glioblastoma, mesothelioma and other solid tumors; and non-Hodgkin's lymphoma (NHL), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), multiple myeloma (MM), acute myeloid leukemia (AML) and other liquid tumors.

[0324] According to an embodiment of the present invention, a therapeutically effective amount of the CAR of the present invention is included in the CAR-T cell or CAR-NK cell, and a therapeutically effective amount of an anti-mesothelin antibody or an antigen-binding fragment thereof (e.g., an anti-mesothelin antibody) is included in the pharmaceutical composition. As used herein, the term "therapeutically effective amount" refers to the amount of an active ingredient or component that causes a desired biological or drug response in a subject. According to the purpose, the therapeutically effective amount can be determined empirically and conventionally.

[0325] As used herein, a therapeutically effective amount of CARs refers to the amount of CAR molecules expressed in transduced T cells or NK cells, which can modulate an immune response in a subject in need thereof. In addition, as used herein, a therapeutically effective amount of CARs refers to a certain amount of CAR molecules expressed in transduced T cells or NK cells, which can treat a disease, disorder, or condition; prevent or slow the progression of a disease, disorder, or condition; or reduce or completely alleviate symptoms associated with a disease, disorder, or condition.

[0326] As used herein, a therapeutically effective amount of CAR-T cells or CAR-NK cells refers to the amount of CAR-T cells or CAR-NK cells that can modulate an immune response in a subject in need thereof. In addition, as used herein, a therapeutically effective amount of CAR-T cells or CAR-NK cells refers to an amount of CAR-T cells or CAR-NK cells that can treat a disease, disorder, or condition; prevent or slow the progression of a disease, disorder, or condition; or reduce or completely alleviate symptoms associated with a disease, disorder, or condition.

[0327] As used herein, a therapeutically effective amount of an anti-mesothelin antibody or antigen-binding fragment thereof refers to an amount of an anti-mesothelin antibody or antigen-binding fragment thereof that is capable of modulating an immune response in a subject in need thereof. In addition, as used herein, a therapeutically effective amount of an anti-mesothelin antibody or antigen-binding fragment thereof refers to an amount of an anti-mesothelin antibody or antigen-binding fragment thereof that can treat a disease, disorder, or condition; prevent or slow the progression of a disease, disorder, or condition; or reduce or completely alleviate symptoms associated with a disease, disorder, or condition.

[0328] According to a specific embodiment, the disease, disorder or condition to be treated is cancer, preferably a cancer selected from the group consisting of lung cancer, gastric cancer, esophageal cancer, bile duct cancer, cholangiocarcinoma, colon cancer, hepatocellular carcinoma, renal cell carcinoma, bladder urothelial carcinoma, metastatic melanoma, breast cancer, ovarian cancer, cervical cancer, head and neck cancer, pancreatic cancer, glioma, glioblastoma, mesothelioma and other solid tumors; and non-Hodgkin's lymphoma (NHL), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), multiple myeloma (MM), acute myeloid leukemia (AML) and other liquid tumors. According to other specific embodiments, the disease, disorder or condition to be treated is inflammatory and / or autoimmune disease.

[0329] According to a specific embodiment, a therapeutically effective amount refers to a therapeutic dose sufficient to achieve one, two, three, four or more of the following effects: (i) reducing or ameliorating the severity of the disease, disorder or condition to be treated or symptoms associated therewith; (ii) shortening the duration of the disease, disorder or condition to be treated or symptoms associated therewith; (iii) preventing the worsening of the disease, disorder or condition to be treated or symptoms associated therewith; (iv) causing the disease, disorder or condition to be treated or symptoms associated therewith to subside; (v) preventing the development or onset of the disease, disorder or condition to be treated or symptoms associated therewith; (vi) ) prevent the recurrence of the disease, disorder or condition to be treated, or symptoms associated therewith; (vii) reduce the frequency of hospitalization of a subject suffering from the disease, disorder or condition to be treated, or symptoms associated therewith; (viii) shorten the length of hospitalization of a subject suffering from the disease, disorder or condition to be treated, or symptoms associated therewith; (ix) increase the survival of a subject suffering from the disease, disorder or condition to be treated, or symptoms associated therewith; (xi) inhibit or alleviate the disease, disorder or condition to be treated, or symptoms associated therewith; and / or (xii) enhance or improve the prophylactic or therapeutic effect of another therapy.

[0330] The therapeutically effective amount or dosage may vary according to various factors, such as the disease, disorder or condition to be treated, the mode of administration, the target site, the physiological state of the subject (including, for example, age, weight, health), whether the subject is human or animal, other drugs administered, and whether the treatment is preventive or therapeutic. The therapeutic dose is optimally titrated to optimize safety and efficacy.

[0331] According to a specific embodiment, the composition described herein is formulated according to the intended administration route of the subject. For example, the composition described herein can be formulated into a preparation suitable for intravenous, subcutaneous or intramuscular administration.

[0332] The cells of the present invention can be administered to a subject in any convenient manner known to those skilled in the art. For example, the cells of the present invention can be administered to a subject by aerosol inhalation, injection, ingestion, transfusion, implantation, and / or transplantation. Compositions comprising the cells of the present invention can be administered intraarterially, subcutaneously, intradermally, intratumorally, intranodally, intramedullary, intramuscularly, intrapleurally, intravenously, or intraperitoneally. In certain embodiments, the cells of the present invention can be administered to a subject that is lymphocyte-depleted or lymphocyte-non-depleted.

[0333] The pharmaceutical composition comprising cells expressing the CARs of the present invention can be provided in the form of a sterile liquid preparation, a typical cell suspension isotonic aqueous solution, or as an emulsion, dispersion, etc., which is usually buffered to a certain pH. The composition may include a carrier, such as water, saline, phosphate-buffered saline, etc., which can maintain the integrity and viability of the cells and is suitable for the administration of the cell composition.

[0334] The preparation of sterile injectable solutions can be by mixing the cells of the present invention with various other ingredients required in an appropriate solvent. The composition may include a pharmaceutically acceptable carrier, diluent or excipient, such as sterile water, normal saline, glucose, dextran, etc., suitable for use with cell components and administered to subjects such as humans. Suitable buffers for providing cell components are well known in the art. Any carrier, diluent or additive used in the present invention has the function of maintaining the integrity and viability of the cells of the present invention.

[0335] The cell of the present invention can be contained in any physiologically acceptable carrier and is administered. The cell group comprising the cell of the present invention can include a purified cell group. Those skilled in the art can easily determine the cell in the cell group using various well-known methods. The purity range of the cell group comprising the genetically modified cell of the present invention can be about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95% or about 95% to about 100%. Dosage can be adjusted by those skilled in the art, for example, the reduction of purity may require an increase in dosage.

[0336] The dosage of the cells of the present invention is usually calculated based on the number of cells administered per kilogram of the subject's body weight (cells / kg). 4 to about 10 10 cells / kg body weight, for example, about 10 5 to about 10 9 , about 10 5 to about 10 8 , about 10 5 to about 10 7 or about 10 5 to about 10 6 , depending on the mode and location of administration. Generally, in the case of systemic administration, a higher dose is administered than in the case of local administration, where the immune cells of the invention are administered in the tumor and / or cancer area. Exemplary dosage ranges include, but are not limited to, 1 x 10 4 Up to 1x 10 8 , 2x 10 4 Up to 1x 10 8 , 3x10 4 Up to 1x 10 8 , 4x 10 4 Up to 1x 10 8 , 5x 10 4 Up to 6x 10 8 , 7x 10 4 Up to 1x 10 8 , 8x 10 4 Up to 1x 10 8 , 9x 10 4 Up to 1x 10 8 , 1x 10 5 Up to 1x 10 8 , 1x 10 5 Up to 9x 10 7 , 1x 10 5 Up to 8x 10 7, 1x 10 5 Up to 7x 10 7 , 1x 10 5 Up to 6x10 7 , 1x 10 5 Up to 5x 10 7 , 1x 10 5 Up to 4x 10 7 , 1x 10 5 Up to 4x 10 7 , 1x 10 5 Up to 3x 10 7 , 1x 10 5 Up to 2x 10 7 , 1x10 5 Up to 1x 10 7 , 1x 10 5 Up to 9x 10 6 , 1x 10 5 Up to 8x 10 6 , 1x 10 5 Up to 7x 10 6 , 1x 10 5 Up to 6x 10 6 , 1x 10 5 Up to 5x 10 6 , 1x 10 5 Up to 4x 10 6 , 1x 10 5 Up to 4x 10 6 , 1x 10 5 Up to 3x 10 6 , 1x 10 5 Up to 2x 10 6 , 1x 10 5 Up to 1x10 6 , 2x 10 5 Up to 9x 10 7 , 2x 10 5 Up to 8x 10 7 , 2x 10 5 Up to 7x 10 7 , 2x 10 5 Up to 6x 10 7 , 2x 10 5 Up to 5x 10 7 , 2x10 5 Up to 4x 10 7 , 2x 10 5 Up to 4x 10 7 , 2x 10 5 Up to 3x 10 7 , 2x 10 5Up to 2x 10 7 , 2x 10 5 Up to 1x 10 7 , 2x 10 5 Up to 9x 10 6 , 2x 10 5 Up to 8x 10 6 , 2x 10 5 Up to 7x 10 6 , 2x 10 5 Up to 6x 10 6 , 2x 10 5 Up to 5x 10 6 , 2x 10 5 Up to 4x10 6 , 2x 10 5 Up to 4x 10 6 , 2x 10 5 Up to 3x 10 6 , 2x 10 5 Up to 2x 10 6 , 2x 10 5 Up to 1x 10 6 , 3x 10 5 Up to 3x 10 6 In addition, the dosage can be adjusted according to a single administration or multiple administrations. Based on the individual differences of the subjects, the precise determination of the effective dose is different.

[0337] As used herein, the terms "treatment", "therapeutic" and "therapeutic method" are all intended to refer to the improvement or reversal of at least one measurable physical parameter associated with cancer, inflammation and / or autoimmune diseases, disorders or conditions, which is not necessarily observed in a subject, but can be observed. The terms "treatment", "therapeutic" and "therapeutic method" may also refer to causing regression of a condition, preventing or at least slowing the progression of a disease, disorder or condition. In a specific embodiment, "treatment", "therapeutic" and "therapeutic method" refer to alleviating, preventing the development or onset of one or more symptoms associated with a disease, disorder or condition such as a tumor or cancer, or shortening its duration. In a specific embodiment, "treatment", "therapeutic" and "therapeutic method" refer to preventing the recurrence of a disease, disorder or condition. In a specific embodiment, "treatment", "therapeutic" and "therapeutic method" refer to increasing the survival of a subject with the disease, disorder or condition. In a specific embodiment, "treatment", "therapeutic" and "therapeutic method" refer to eliminating the disease, disorder or condition of the subject.

[0338] According to a specific embodiment, a composition for treating cancer, inflammation and / or autoimmune diseases, disorders or conditions is provided. For cancer treatment, the provided composition can be used in combination with other treatment methods, including but not limited to: chemotherapy, anti-CD20 monoclonal antibody, anti-TIM-3 monoclonal antibody, anti-LAG-3 monoclonal antibody, anti-EGFR monoclonal antibody, anti-HER-2 monoclonal antibody, anti-CD19 monoclonal antibody, anti-CD33 monoclonal antibody, anti-CD47 monoclonal antibody, anti-CD73 monoclonal antibody, anti-DLL-3 monoclonal antibody, anti-apelin monoclonal antibody, anti-FOLR-1 monoclonal antibody, anti-CTLA-4 monoclonal antibody, anti-PD-L1 monoclonal antibody, anti-PD-1 monoclonal antibody, anti-Claudin 18.2 monoclonal antibody, other immuno-oncology drugs, anti-angiogenic agents, radiotherapy, antibody-drug conjugates (ADC), targeted therapy or other anti-cancer drugs. Antibodies against mesothelin can be combined with monoclonal antibodies against PD-1, PD-L1, LAG3, TIM-3, CTLA-4, EGFR, HER-2, CD19, CD20, CD33, CD73, CD47, CD3, apelin, DLL-3, TIP-1, GPC3, Claudin 18.2, folate receptor alpha (FOLR1), MUC16, 5T4, PSCA, IL13Ra2, EGFRvIII, p95HER2 and / or any other tumor-associated antigen (TAA) to construct bispecific antibodies to treat cancers / tumors expressing both antigens. Two antibodies that recognize two different epitopes on mesothelin can also be used to construct bispecific antibodies to treat cancers / tumors expressing mesothelin.

[0339] According to a specific embodiment, a method for treating cancer in a subject in need thereof comprises administering to the subject the CAR-T cells and / or CAR-NK cells of the present invention in combination with an agent having the effect of increasing cell expression of CAR molecules. These drugs include, but are not limited to, antibody fragments that bind CD73, CD39, PD1, PD-L1, PD-L2, CTLA4, TIM3 or LAG3, or adenosine A2a receptor antagonists.

[0340] According to a specific embodiment, a method for treating cancer in a subject in need includes administering the CAR-T cells and / or CAR-NK cells of the present invention in combination with a drug that improves one or more side effects to the subject, the side effects being associated with administering cells expressing CAR molecules. Such drugs include, but are not limited to, steroids, TNFα inhibitors, or IL-6 inhibitors.

[0341] According to a specific embodiment, a method for treating cancer in a subject in need thereof comprises administering to the subject the CAR-T cells and / or CAR-NK cells of the present invention in combination with a drug for treating a mesothelin-related disease. Such drugs include, but are not limited to, anti-mesothelin monoclonal antibodies or bispecific antibodies.

[0342] As used herein, the term "combination" refers to the use of more than one therapy in the context of applying two or more therapies to a subject. The use of the term "combination" does not limit the order in which the treatment method is applied to a subject. For example, the first treatment of a subject (e.g., a composition as described herein) can be before the second treatment (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 16 hours, 24 hours, 48 ​​hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks or 12 weeks before), or simultaneously with the second treatment, or after the second treatment (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 16 hours, 24 hours, 48 ​​hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks or 12 weeks after).

[0343] In another general aspect, the present invention relates to a method for determining the level of mesothelin in a subject. The method comprises: (a) obtaining a sample from the subject; (b) contacting the sample with the monoclonal antibody or antigen-binding fragment of the present invention; (c) determining the level of mesothelin in the subject.

[0344] As used herein, "sample" refers to a biological sample isolated from a subject, and may include, but is not limited to, whole blood, serum, plasma, blood cells, endothelial cells, tissue biopsy (e.g., cancer tissue), lymph, ascites, tissue fluid, bone marrow, cerebrospinal fluid, saliva, mucus, sputum, sweat, urine, or any other secretion, excretion, or other body fluid. "Blood sample" refers to whole blood or any portion thereof, including blood cells, serum, and plasma.

[0345] In certain embodiments, the level of mesothelin in a subject may be determined using, but not limited to, Western blot assays, immunohistochemistry (IHC), and ELISA assays. Relative protein levels may be determined by Western blot analysis and immunohistochemistry (IHC), and absolute protein levels may be determined by ELISA. When determining the relative level of mesothelin, the level of mesothelin may be determined by at least two samples, for example, samples from the same subject at different time points, samples from different tissues of the same subject, and / or samples from different subjects. Alternatively, when determining the absolute level of mesothelin, for example, by ELISA assay, the absolute level of mesothelin in the sample may be determined by creating an ELISA assay standard prior to testing the sample. One skilled in the art will understand which analytical techniques should be used to determine the level of mesothelin in a sample from a subject using the antibodies or antigen-binding fragments of the present invention.

[0346] By using the method for determining the level of mesothelin in a subject sample, it is possible to diagnose abnormal (increased, decreased or insufficient) levels of mesothelin in a disease and make appropriate treatment decisions. The disease may be, but is not limited to, cancer, inflammatory disease or autoimmune disease. In addition, based on the knowledge of the level of mesothelin during the progression of a specific disease and / or a specific disease, by monitoring the level of mesothelin in a subject, the risk of occurrence of the above-mentioned disease can be determined.

[0347] Implementation

[0348] The present invention also provides the following non-limiting embodiments.

[0349] Embodiment 1 is an isolated monoclonal antibody or an antigen-binding fragment thereof, comprising a heavy chain variable region, the heavy chain variable region comprising a heavy chain complementary determining region 1 (HCDR1), HCDR2, and HCDR3; and a light chain variable region, the light chain variable region comprising a light chain complementary determining region 1 (LCDR1), LCDR2, and LCDR3, each having a polypeptide sequence:

[0350] (1) SEQ ID NO: 3, 4, 5, 6, 7 and 8, or SEQ ID NO: 9, 10, 11, 12, 13 and 14;

[0351] (2) SEQ ID NOs: 17, 18, 19, 20, 21 and 22, or SEQ ID NOs: 23, 24, 25, 26, 27 and 28;

[0352] (3) SEQ ID NOs: 31, 32, 33, 34, 35 and 36, or SEQ ID NOs: 37, 38, 39, 40, 41 and 42; or

[0353] (4) SEQ ID NOs: 60, 61, 62, 63, 64 and 65, or SEQ ID NOs: 66, 67, 68, 69, 70 and 71;

[0354] Wherein, the antibody or antigen-binding fragment thereof specifically binds to mesothelin, preferably specifically binds to human mesothelin.

[0355] Embodiment 2 is the isolated monoclonal antibody or antigen-binding fragment thereof described in embodiment 1, comprising a heavy chain variable region having a polypeptide sequence that is at least 95% identical to SEQ ID NO: 1, 15, 29 or 58; or a light chain variable region having a polypeptide sequence that is at least 95% identical to SEQ ID NO: 2, 16, 30 or 59.

[0356] Embodiment 3 is the isolated monoclonal antibody or antigen-binding fragment thereof described in any one of embodiments 1-2, comprising:

[0357] (1) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 1 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 2;

[0358] (2) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 15 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 16;

[0359] (3) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 29 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 30; or

[0360] (4) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 58 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 59.

[0361] Embodiment 4 is the isolated monoclonal antibody or antigen-binding fragment thereof as described in any one of embodiments 1-3, wherein the antibody or antigen-binding fragment thereof is chimeric and / or human or humanized.

[0362] Embodiment 5 is the isolated monoclonal antibody or antigen-binding fragment thereof described in embodiment 4, wherein the humanized monoclonal antibody or antigen-binding fragment thereof comprises: a heavy chain variable region having a polypeptide sequence at least 95% identical to any one of SEQ ID NOs: 43-46, 52-55 or 72-75; or a light chain variable region having a polypeptide sequence at least 95% identical to any one of SEQ ID NOs: 47-51, 56-57 or 76-78.

[0363] Embodiment 6 is the isolated monoclonal antibody or antigen-binding fragment thereof of embodiment 5, wherein the humanized monoclonal antibody or antigen-binding fragment thereof comprises:

[0364] (1) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 43 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 47;

[0365] (2) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 43 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 48;

[0366] (3) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 43 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 49;

[0367] (4) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 43 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 50;

[0368] (5) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 43 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 51;

[0369] (6) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 44 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 47;

[0370] (7) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 44 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 48;

[0371] (8) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 44 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 49;

[0372] (9) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 44 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 50;

[0373] (10) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 44 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 51;

[0374] (11) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 45 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 47;

[0375] (12) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 45 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 48;

[0376] (13) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 45 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 49;

[0377] (14) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 45 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 50;

[0378] (15) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 45 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 51;

[0379] (16) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 46 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 47;

[0380] (17) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 46 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 48;

[0381] (18) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 46 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 49;

[0382] (19) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 46 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 50;

[0383] (20) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 46 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 51;

[0384] (21) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 52 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 56;

[0385] (22) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 52 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 57;

[0386] (23) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 53 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 56;

[0387] (24) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 53 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 57;

[0388] (25) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 54 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 56;

[0389] (26) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 54 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 57;

[0390] (27) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 55 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 56;

[0391] (28) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 55 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 57;

[0392] (29) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 72 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 76;

[0393] (30) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 72 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 77;

[0394] (31) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 72 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 78;

[0395] (32) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 73 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 76;

[0396] (33) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 73 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 77;

[0397] (34) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 73 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 78;

[0398] (35) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 74 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 76;

[0399] (36) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 74 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 77;

[0400] (37) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 74 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 78;

[0401] (38) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 75 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 76;

[0402] (39) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 75 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 77; or

[0403] (40) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 75 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 78.

[0404] Embodiment 7 is the isolated monoclonal antibody or its antigen-binding fragment as described in any one of embodiments 1-6, wherein the isolated antibody or its antigen-binding fragment can induce tumor cell lysis through antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) and / or complement-dependent cytotoxicity (CDC); and / or mediate the recruitment of conjugated drugs, and / or form a bispecific antibody with another monoclonal antibody (mAb) or its antigen-binding fragment having cancer killing effect.

[0405] Embodiment 8 is an isolated bispecific antibody or antigen-binding fragment thereof, which comprises the monoclonal antibody or antigen-binding fragment thereof described in any one of embodiments 1-7.

[0406] Embodiment 9 is an isolated nucleic acid encoding the monoclonal antibody or antigen-binding fragment described in any one of embodiments 1-7 or the bispecific antibody or antigen-binding fragment described in embodiment 8.

[0407] Embodiment 10 is a vector comprising the isolated nucleic acid described in embodiment 9.

[0408] Embodiment 11 is a host cell comprising the vector described in embodiment 10.

[0409] Embodiment 12 is a pharmaceutical composition, which comprises the isolated monoclonal antibody or antigen-binding fragment described in any one of embodiments 1-7, or the bispecific antibody or antigen-binding fragment thereof described in embodiment 8, and a pharmaceutically acceptable carrier.

[0410] Embodiment 13 is a method for targeting mesothelin on the surface of cancer cells, and / or treating cancer, treating inflammatory diseases and / or treating autoimmune diseases in a subject in need thereof, comprising administering to the subject the pharmaceutical composition of embodiment 12, optionally, wherein the cancer is selected from the group consisting of lung cancer, gastric cancer, esophageal cancer, bile duct cancer, cholangiocarcinoma, cholangiocellular carcinoma, colon cancer, hepatocellular carcinoma, renal cell carcinoma, bladder urothelial carcinoma, metastatic melanoma, breast cancer, ovarian cancer, cervical cancer, head and neck cancer, pancreatic cancer, glioma, glioblastoma, mesothelioma and other solid tumors, as well as non-Hodgkin's lymphoma (NHL), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), multiple myeloma (MM), acute myeloid leukemia (AML) and other liquid tumors.

[0411] Embodiment 14 is a method for preparing the monoclonal antibody or antigen-binding fragment described in any one of embodiments 1-7 or the bispecific antibody or antigen-binding fragment described in embodiment 8, comprising culturing cells containing nucleic acids encoding the monoclonal antibody or antigen-binding fragment thereof or bispecific antibody or antigen-binding fragment thereof under conditions for preparing the monoclonal antibody or antigen-binding fragment thereof or bispecific antibody or antigen-binding fragment thereof, and recovering the monoclonal antibody or antigen-binding fragment thereof or bispecific antibody or antigen-binding fragment thereof from the cells or culture.

[0412] Embodiment 15 is a method for preparing a pharmaceutical composition, which comprises the monoclonal antibody or antigen-binding fragment thereof described in any one of embodiments 1-7 or the bispecific antibody or antigen-binding fragment thereof described in embodiment 8, comprising combining the monoclonal antibody or antigen-binding fragment thereof or the bispecific antibody or antigen-binding fragment thereof with a pharmaceutically acceptable carrier to obtain the pharmaceutical composition.

[0413] Embodiment 16 is a method for determining the level of mesothelin in a subject, the method comprising:

[0414] (1) Obtaining samples from subjects;

[0415] (2) contacting the sample with the isolated monoclonal antibody or antigen-binding fragment thereof described in any one of embodiments 1-7; and

[0416] (3) Determine the level of mesothelin in the subjects.

[0417] Embodiment 17 is the method of embodiment 16, wherein the sample is a tissue sample or a blood sample, and the tissue sample is optionally a cancer tissue sample.

[0418] Embodiment 18 is an isolated polynucleotide comprising a nucleic acid sequence encoding a chimeric antigen receptor (CAR), wherein the CAR comprises:

[0419] (a) an extracellular domain comprising at least one antigen binding domain that specifically binds to mesothelin;

[0420] (b) hinge region;

[0421] (c) a transmembrane region; and

[0422] (d) Intracellular signal transduction domain.

[0423] Embodiment 19 is the isolated polynucleotide of embodiment 18, wherein the antigen binding domain comprises a heavy chain variable region comprising heavy chain complementary determining region 1 (HCDR1), HCDR2, HCDR3, and a light chain variable region comprising light chain complementary determining region 1 (LCDR1), LCDR2, and LCDR3, each having a polypeptide sequence:

[0424] (1) SEQ ID NO: 3, 4, 5, 6, 7 and 8, or SEQ ID NO: 9, 10, 11, 12, 13 and 14;

[0425] (2) SEQ ID NOs: 17, 18, 19, 20, 21 and 22, or SEQ ID NOs: 23, 24, 25, 26, 27 and 28;

[0426] (3) SEQ ID NOs: 31, 32, 33, 34, 35 and 36, or SEQ ID NOs: 37, 38, 39, 40, 41 and 42;

[0427] (4) SEQ ID NOs: 60, 61, 62, 63, 64 and 65, or SEQ ID NOs: 66, 67, 68, 69, 70 and 71;

[0428] Wherein, the antigen binding domain specifically binds to mesothelin, preferably human mesothelin.

[0429] Embodiment 20 is an isolated polynucleotide as described in embodiment 18 or 19, wherein the antigen binding domain comprises a heavy chain variable region having a polypeptide sequence at least 95% identical to SEQ ID NO: 1, 15, 29, 58, 43-46, 52-55 or 72-75, or a light chain variable region having a polypeptide sequence at least 95% identical to SEQ ID NO: 2, 16, 30, 59, 47-51, 56-57, or 76-78.

[0430] Embodiment 21 is the isolated polynucleotide of embodiment 20, wherein the antigen binding domain comprises:

[0431] (1) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 1 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 2;

[0432] (2) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 15 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 16;

[0433] (3) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 29 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 30;

[0434] (4) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 58 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 59;

[0435] (5) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 43 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 47;

[0436] (6) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 43 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 48;

[0437] (7) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 43 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 49;

[0438] (8) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 43 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 50;

[0439] (9) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 43 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 51;

[0440] (10) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 44 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 47;

[0441] (11) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 44 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 48;

[0442] (12) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 44 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 49;

[0443] (13) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 44 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 50;

[0444] (14) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 44 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 51;

[0445] (15) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 45 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 47;

[0446] (16) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 45 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 48;

[0447] (17) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 45 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 49;

[0448] (18) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 45 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 50;

[0449] (19) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 45 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 51;

[0450] (20) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 46 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 47;

[0451] (21) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 46 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 48;

[0452] (22) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 46 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 49;

[0453] (23) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 46 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 50;

[0454] (24) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 46 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 51;

[0455] (25) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 52 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 56;

[0456] (26) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 52 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 57;

[0457] (27) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 53 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 56;

[0458] (28) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 53 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 57;

[0459] (29) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 54 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 56;

[0460] (30) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 54 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 57;

[0461] (31) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 55 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 56;

[0462] (32) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 55 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 57;

[0463] (33) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 72 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 76;

[0464] (34) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 72 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 77;

[0465] (35) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 72 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 78;

[0466] (36) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 73 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 76;

[0467] (37) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 73 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 77;

[0468] (38) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 73 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 78;

[0469] (39) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 74 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 76;

[0470] (40) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 74 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 77;

[0471] (41) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 74 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 78;

[0472] (42) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 75 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 76;

[0473] (43) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 75 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 77; or

[0474] (44) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 75 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 78.

[0475] Embodiment 22 is the isolated polynucleotide of any one of embodiments 18-21, wherein the antigen binding domain is a single chain variable fragment (scFv).

[0476] Embodiment 23 is the isolated polynucleotide of embodiment 22, wherein the single-chain variable fragment (scFv) is humanized.

[0477] Embodiment 24 is an isolated polynucleotide as described in any one of embodiments 18-23, wherein the chimeric antigen receptor (CAR) comprises one or more antigen binding domains, and / or its intracellular signaling domain comprises one or more co-stimulatory domains and one or more activation domains.

[0478] Embodiment 25 is a chimeric antigen receptor (CAR) encoded by the isolated polynucleotide described in any one of embodiments 18-24.

[0479] Embodiment 26 is a vector comprising the isolated polynucleotide described in any one of embodiments 18-24.

[0480] Embodiment 27 is a host cell comprising the vector described in embodiment 26, wherein the cell is optionally a T cell or a NK cell, preferably a human T cell or a human NK cell.

[0481] Embodiment 28 is a method for preparing a host cell expressing a chimeric antigen receptor (CAR), the method comprising transducing T cells or NK cells with the vector described in embodiment 26.

[0482] Embodiment 29 is a method for preparing chimeric antigen receptor (CAR)-T cells or chimeric antigen receptor (CAR)-NK cells, the method comprising culturing T cells or NK cells containing isolated polynucleotides under conditions for preparing CAR-T cells or CAR-NK cells, wherein the polynucleotides contain a nucleic acid encoding the chimeric antigen receptor (CAR) described in any of embodiments 18-24, and recovering the CAR-T cells or CAR-NK cells.

[0483] Embodiment 30 is a method for preparing a cell comprising a chimeric antigen receptor (CAR), the method comprising contacting the cell with an isolated polynucleotide, the polynucleotide comprising a nucleic acid encoding the chimeric antigen receptor (CAR) described in any one of embodiments 18-24, and the polynucleotide is in vitro transcribed RNA or synthetic RNA.

[0484] Embodiment 31 is a method for treating cancer in a subject in need thereof, comprising administering the host cell of embodiment 27 to a subject in need thereof, optionally wherein the cancer is selected from lung cancer, gastric cancer, esophageal cancer, bile duct cancer, cholangiocarcinoma, cholangiocarcinoma, colon cancer, hepatocellular carcinoma, renal cell carcinoma, bladder urothelial carcinoma, metastatic melanoma, breast cancer, ovarian cancer, cervical cancer, head and neck cancer, pancreatic cancer, glioma, glioblastoma, mesothelioma and other solid tumors, as well as non-Hodgkin's lymphoma (NHL), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), multiple myeloma (MM), acute myeloid leukemia (AML) and other liquid tumors.

[0485] Embodiment 32 is the method described in embodiment 31, which further comprises administering to a subject in need thereof a drug having the efficacy of increasing cell expression of CAR, or a drug that improves one or more side effects associated with the administration of cells expressing CAR molecules, or a drug for treating a disease associated with mesothelin. Example

[0486] Example 1: Identification of anti-mesothelin monoclonal antibodies

[0487] Mice are immunized with the antigen, hybridomas are generated, and screened by ELISA and / or FACS. Positive clones are isolated and sequenced.

[0488] The sequences of the heavy chain and light chain variable regions (VH region and VL region, respectively) of the anti-mesothelin monoclonal antibodies are shown in Tables 1 and 2, and the sequences of the CDR regions of the anti-mesothelin monoclonal antibodies are shown in Tables 3-6.

[0489] Table 1: Anti-mesothelin mAb heavy chain variable region sequences

[0490]

[0491] VH: heavy chain variable region

[0492] Table 2: Sequences of light chain variable regions of anti-mesothelin monoclonal antibodies

[0493]

[0494] VH: light chain variable region

[0495] Table 3: Anti-mesothelin mAb Heavy Chain CDR Regions 1-3

[0496]

[0497] HC: heavy chain; CDR: complementarity determining region; NO: SEQ ID NO

[0498] HC CDRs of anti-mesothelin monoclonal antibody were determined by IMGT method

[0499] (Lefranc, M.-P. et al., Nucleic Acids Research, 1999; 27: 209-212)

[0500] Table 4: Anti-mesothelin mAb light chain CDR regions 1-3

[0501]

[0502] LC: light chain; CDR: complementarity determining region; NO: SEQ ID NO

[0503] LC CDRs of anti-mesothelin monoclonal antibody were determined by IMGT method

[0504] (Lefranc, M.-P. et al., Nucleic Acids Research, 1999; 27: 209-212)

[0505] Table 5: Anti-mesothelin mAb Heavy Chain CDR Regions 1-3

[0506]

[0507] HC: heavy chain; CDR: complementarity determining region; NO: SEQ ID NO

[0508] The HC CDRs of the anti-mesothelin monoclonal antibody were determined using the Kabat method (Elvin A. Kabat et al., Immunologically Related Protein Sequences, 5th Edition, 1991)

[0509] Table 6: Anti-mesothelin mAb Light Chain CDR Regions 1-3

[0510] mAb cloning LC CDR1 NO LC CDR2 NO LC CDR3 NO 10F5 RASQDISNYLN 12 YTSRLHS 13 QQYSQLPYT 14 4F8 KASENVGTYIS 26 GASNRYT 27 GQSYNYPFT 28 9D5 KSSQSLLYSDGKTYLN 40 QVSKLDP 41 LQGTYYPHT 42 2G11 KASENVGSYVS 69 GASNRYT 70 GQSYSYPYT 71

[0511] LC: heavy chain; CDR: complementarity determining region; NO: SEQ ID NO

[0512] LC CDRs of anti-mesothelin mAb were determined by Kabat method

[0513] (Elvin A. Kabat et al., Immunologically Related Protein Sequences 5th Edition, 1991)

[0514] Example 2: Preparation and purification of monoclonal antibodies from culture medium of transfected cells

[0515] Recombinant anti-mesothelin chimeric monoclonal antibodies were obtained by transiently transfecting expression vectors containing mouse variable regions (VH and VL) fused to the constant regions of human IgG1 heavy chain and kappa light chain, respectively, into ExpiCHO-S or Expi293F cells. The recombinant antibodies produced in ExpiCHO-S or Expi293F cell suspensions were purified using protein A affinity chromatography.

[0516] Example 3: ELISA binding analysis of purified chimeric mAbs

[0517] The purified chimeric monoclonal antibody was tested for its ability to bind to immobilized mesothelin by ELISA. Recombinant human mesothelin (ACRO Biosystems, human mesothelin (296-580), catalog number: MSN-H5223) (diluted with DPBS buffer) was coated on a 96-well plate and allowed to stand at room temperature for 1 hour. The wells were blocked with 5% BSA (diluted with TBST) for 1 hour at room temperature. In each well of a single plate, different concentrations of monoclonal antibodies were incubated at room temperature for 1 hour. After the wells were washed, the monoclonal antibody was detected for binding to mesothelin using mouse anti-human IgG Fc antibody (50B4A9) [HRP] and monoclonal antibody (Genescript, Piscataway, New Jersey; batch number: A01854) at room temperature for 1 hour. After washing, ELISA was performed using one-step detection solution (ThermoFisher Scientific, lot number: 34028) and absorbance was measured at 450 nm; or ELISA was performed using QuantaBlu fluorescent peroxidase substrate kit (Thermo, lot number: 15169) and fluorescence was detected at 325 nm and 420 nm. Figures 1A-1D .

[0518] Example 4: FACS binding analysis of purified monoclonal antibodies

[0519] Approximately 100,000 NCI-N87 cells or 50,000 NCI-H226 cells were transferred to a 96-well plate and incubated with different concentrations of purified chimeric anti-mesothelin monoclonal antibodies (variable regions of mouse monoclonal antibodies fused to the constant regions of human IgG1 heavy chain and kappa light chain, respectively) at 4°C for 15 minutes. The cells were then centrifuged for 5 minutes and washed three times with FACS buffer (HBSS supplemented with 5% BSA and 0.05% sodium azide). The cells were then incubated with PE / Cyanine7 anti-human IgG Fc recombinant antibody (clone QA19A42) (Biolegend, San Diego, CA; Cat. No.: 366907) or AlexaFluor 488 anti-human IgG Fc F(ab')2 (Thermo; Cat. No.: H10120) and incubated on ice for another 15 minutes. The cells were then washed twice with FACS buffer and resuspended in FACS buffer. The cells were then run on the Attune NxT and the data analyzed by the Attune NxT software. Figure 2A-2C .

[0520] Example 5: Humanization of anti-mesothelin monoclonal antibody

[0521] Mouse anti-mesothelin monoclonal antibodies were humanized to reduce the potential for immunogenicity when administered to human patients. The heavy and light chain variable region (VH and VL) sequences were aligned with human antibody sequences in the Protein Data Bank (PDB) database to establish a homology model. The CDRs in the heavy and light chains of the mouse monoclonal antibody were transplanted into the human framework that is most likely to maintain the appropriate structure required for antigen binding. If necessary, reverse mutations or other mutations from human residues to mouse residues were designed. The sequences of the humanized VH and VL regions are shown in Table 7. The humanized VH and VL regions were fused to the constant regions of the human IgG1 heavy chain and kappa light chain, respectively. The ELISA method previously described in Examples 3 and 4 ( Figures 3A-3E ) and FACS assay ( Figures 4A-4E ) to detect the binding of humanized monoclonal antibodies to mesothelin. 10F5-H1L1 is a humanized monoclonal antibody constructed by the 10F5-H1 heavy chain and 10F5-L1 light chain in Table 7; other humanized clones also follow the same naming rules.

[0522] Table 7: Humanized anti-mesothelin mAb heavy chain and light chain variable region sequences

[0523]

[0524]

[0525] NO:SEQ ID NO.

[0526] Example 6: Construction of chimeric antigen receptor constructs containing an anti-mesothelin antigen binding domain

[0527] The monoclonal antibody is converted into scFv using VH, VL and (G4S) n linker, and the scFv is fused to the hinge and N-terminus of the transmembrane domain of human CD8a (aa 114-118, Boursier et al., J. Biol. Chem, 268 (3): 2013-20 (1993)), thereby constructing CAR. The C-terminal intracellular signal transduction domain of CAR is constructed by fusing the intracellular costimulatory domain of CD28 (aa162-202, Aruffo A and Seed B, Proc. Natl. Acad. Sci. USA 84 (23): 8573-7 (1987)) and the activation domain derived from the subsequent CD3 ζ chain (aa 52-162, Letourneur F and Klausner RD, Proc. Natl. Acad. Sci. USA 88 (20): 8905-9 (1991)). Using standard molecular biology cloning techniques, the DNA sequence encoding the CAR is assembled and cloned into an expression vector (retroviral, lentiviral, extrachromosomal or integrating) to generate a CAR construct.

[0528] Those skilled in the art will appreciate that the above embodiments may be modified without departing from the broad inventive concept thereof. Therefore, it should be understood that the invention is not limited to the specific embodiments disclosed, and is intended to cover modifications to the content and scope of the invention described as defined by this specification.

Claims

1. An isolated monoclonal antibody or antigen-binding fragment or antigen-binding domain thereof, comprising a heavy chain variable region, the heavy chain variable region comprising a heavy chain complementary determining region 1 (HCDR1), HCDR2, HCDR3, and a light chain variable region, the light chain variable region comprising a light chain complementary determining region 1 (LCDR1), LCDR2 and LCDR3, each having a polypeptide sequence: (1) SEQ ID NO: 3, 4, 5, 6, 7 and 8, or SEQ ID NO: 9, 10, 11, 12, 13 and 14; (2) SEQ ID NOs: 17, 18, 19, 20, 21 and 22, or SEQ ID NOs: 23, 24, 25, 26, 27 and 28; (3) SEQ ID NOs: 31, 32, 33, 34, 35 and 36, or SEQ ID NOs: 37, 38, 39, 40, 41 and 42; (4) SEQ ID NOs: 60, 61, 62, 63, 64 and 65, or SEQ ID NOs: 66, 67, 68, 69, 70 and 71; in, The antibody or antigen-binding fragment or antigen-binding domain thereof specifically binds to mesothelin, preferably human mesothelin.

2. The isolated monoclonal antibody or antigen-binding fragment or antigen-binding domain thereof of claim 1, comprising a heavy chain variable region having a polypeptide sequence at least 95% identical to SEQ ID NO: 1, 15, 29, 43-46, 52-55, 58, or 72-75, or a light chain variable region having a polypeptide sequence at least 95% identical to SEQ ID NO: 2, 16, 30, 47-51, 56-57, 59, or 76-78.

3. The isolated monoclonal antibody or antigen-binding fragment or antigen-binding domain thereof according to claim 1 or 2, include: (a) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 1 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 2; (b) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 15 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 16; (c) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 29 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 30; (d) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 58 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 59; (e) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 43 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 47; (f) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 43 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 48; (g) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 43 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 49; (h) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 43 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 50; (i) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 43 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 51; (j) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 44 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 47; (k) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 44 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 48; (l) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 44 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 49; (m) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 44 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 50; (n) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 44 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 51; (o) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 45 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 47; (p) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 45 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 48; (q) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 45 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 49; (r) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 45 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 50; (s) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 45 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 51; (t) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 46 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 47; (u) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 46 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 48; (v) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 46 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 49; (w) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 46 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 50; (x) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 46 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 51; (y) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 52 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 56; (z) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 52 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 57; (aa) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 53 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 56; (bb) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 53 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 57; (cc) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 54 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 56; (dd) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 54 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 57; (ee) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 55 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 56; (ff) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 55 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 57; (gg) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 72 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 76; (hh) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 72 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 77; (ii) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 72 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 78; (jj) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 73 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 76; (kk) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 73 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 77; (ll) a heavy chain variable region having the polypeptide sequence of SEQ ID NO:73 and a light chain variable region having the polypeptide sequence of SEQ ID NO:78; (mm) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 74 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 76; (nn) a heavy chain variable region having a polypeptide sequence of SEQ ID NO: 74 and a light chain variable region having a polypeptide sequence of SEQ ID NO: 77; (oo) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 74 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 78; (pp) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 75 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 76; (qq) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 75 and a light chain variable region having the polypeptide sequence of SEQ ID NO: 77; or (rr) a heavy chain variable region having the polypeptide sequence of SEQ ID NO: 75 and a light chain variable region having the polypeptide sequence of SEQ ID NO:

78.

4. The isolated monoclonal antibody or antigen-binding fragment or antigen-binding domain thereof according to any one of claims 1 to 3, in, The antibody or antigen-binding fragment or antigen-binding domain thereof is chimeric or human or humanized.

5. The isolated monoclonal antibody or antigen-binding fragment or antigen-binding domain thereof according to any one of claims 1 to 4, in, The antibody or antigen-binding fragment or its antigen-binding domain can induce effector-mediated tumor cell lysis through antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) and / or complement-dependent cytotoxicity (CDC), and / or mediate the recruitment of conjugated drugs, and / or form a bispecific antibody with another monoclonal antibody (mAb) or its antigen-binding fragment having cancer-killing effect.

6. A bispecific antibody or antigen-binding fragment or a bispecific antigen-binding domain thereof, comprising the monoclonal antibody or antigen-binding fragment or an antigen-binding domain thereof according to any one of claims 1 to 5.

7. An isolated nucleic acid encoding the monoclonal antibody or antigen-binding fragment or antigen-binding domain thereof according to any one of claims 1 to 5, or the bispecific antibody or antigen-binding fragment or bispecific antigen-binding domain thereof according to claim 6.

8. A vector comprising the isolated nucleic acid of claim 7.

9. A host cell comprising the vector of claim 8.

10. A pharmaceutical composition comprising the isolated monoclonal antibody or antigen-binding fragment or antigen-binding domain thereof according to any one of claims 1 to 5, or the bispecific antibody or antigen-binding fragment or bispecific antigen-binding domain thereof according to claim 6, and a pharmaceutically acceptable carrier.

11. A method for targeting mesothelin on the surface of cancer cells in a subject in need thereof, and / or treating cancer, and / or treating inflammatory diseases, and / or treating autoimmune diseases, comprising administering to the subject a pharmaceutical composition as described in claim 10, optionally, wherein the cancer is selected from the group consisting of lung cancer, gastric cancer, esophageal cancer, bile duct cancer, cholangiocarcinoma, cholangiocellular carcinoma, colon cancer, hepatocellular carcinoma, renal cell carcinoma, bladder urothelial carcinoma, metastatic melanoma, breast cancer, ovarian cancer, cervical cancer, head and neck cancer, pancreatic cancer, glioma, glioblastoma, mesothelioma and other solid tumors, as well as non-Hodgkin's lymphoma (NHL), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), multiple myeloma (MM), acute myeloid leukemia (AML) and other liquid tumors.

12. A method for preparing the monoclonal antibody or antigen-binding fragment or antigen-binding domain thereof as claimed in any one of claims 1 to 5, or the bispecific antibody or antigen-binding fragment or bispecific antigen-binding domain thereof as claimed in claim 6, the method comprising culturing a cell comprising a nucleic acid encoding the monoclonal antibody or antigen-binding fragment or antigen-binding domain thereof or the bispecific antibody or antigen-binding fragment or bispecific antigen-binding domain thereof under conditions for preparing the monoclonal antibody or antigen-binding fragment or antigen-binding domain thereof or the bispecific antibody or antigen-binding fragment or bispecific antigen-binding domain thereof, and recovering the monoclonal antibody or antigen-binding fragment or antigen-binding domain thereof or the bispecific antibody or antigen-binding fragment or bispecific antigen-binding domain thereof from the cell or culture.

13. A method for preparing a pharmaceutical composition, the pharmaceutical composition comprising the monoclonal antibody or antigen-binding fragment or antigen-binding domain thereof as described in any one of claims 1 to 5, or the bispecific antibody or antigen-binding fragment or bispecific antigen-binding domain thereof as described in claim 6, the method comprising combining the monoclonal antibody or antigen-binding fragment or antigen-binding domain thereof or the bispecific antibody or antigen-binding fragment or bispecific antigen-binding domain thereof with a pharmaceutically acceptable carrier to obtain the pharmaceutical composition.

14. A method for determining the level of mesothelin in a subject, the method comprising: (a) obtaining a sample from a subject; (b) contacting the sample with the isolated monoclonal antibody or antigen-binding fragment or antigen-binding domain thereof according to any one of claims 1 to 5; and (c) determining the level of mesothelin in the subject; in, The sample is optionally a tissue sample or a blood sample, wherein the tissue sample is optionally a cancer tissue sample.

15. An isolated polynucleotide comprising a nucleic acid sequence encoding a chimeric antigen receptor (CAR), wherein the CAR include: (a) an extracellular domain comprising at least one antigen-binding domain according to any one of claims 1 to 5, or a bispecific antigen-binding domain according to claim 6; (b) hinge region; (c) a transmembrane region; and (d) Intracellular signal transduction domain.

16. A chimeric antigen receptor (CAR) encoded by the isolated polynucleotide of claim 15.

17. A host cell comprising a vector comprising the isolated polynucleotide of claim 15, in, The host cell is optionally a T cell or a NK cell, preferably a human T cell or a human NK cell.

Citation Information

Patent Citations

  • Activation and expansion of cells

    US20060121005A1

  • Rapid expansion method ("REM") for in vitro propagation of T lymphocytes

    US5827642A

  • Methods for selectively stimulating proliferation of T cells

    US5858358A

  • CD9 antigen peptides and antibodies thereto

    US5883223A

  • High efficiency transduction of T lymphocytes using rapid expansion methods ("REM")

    US6040177A